

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

## Comparison of anti-vascular endothelial growth factor treatment for myopia choroidal neovascularization: a systematic review and meta-analysis of randomized controlled trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-067921
Article Type:	Original research
Date Submitted by the Author:	02-Sep-2022
Complete List of Authors:	Dong, Liming; Beijing Tongren Hospital, Department of Pharmacy Li, Guangyao; Beijing Tongren Hospital Song, Zhihui; Beijing Tongren Hospital Cheng, Xiao; Beijing Tongren Hospital Bai, Jie; Beijing Tongren Hospital Zhang, Chao; Beijing Tongren Hospital
Keywords:	OPHTHALMOLOGY, CLINICAL PHARMACOLOGY, Medical retina < OPHTHALMOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Comparison of anti-vascular endothelial growth factor treatment for myopia choroidal neovascularization: a systematic review and meta-analysis of randomized controlled trials

Liming Dong<sup>1</sup>, Guangyao Li<sup>1</sup>, Zhihui Song<sup>1</sup>, Xiao Cheng<sup>1</sup>, Jie Bai<sup>1</sup>, Chao Zhang<sup>1</sup>

Running title: Anti-VEGF treatment for myopia CNV

Word count: 2643

Professor Chao Zhang; zctryy@163.com

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

<sup>&</sup>lt;sup>1</sup> Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China **Correspondence to** 

# ABSTRACT

**Objectives** To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF), especially to compare the efficacy of different anti-VEGF retreatment regimens in patients with myopia choroidal neovascularization (CNV).

**Data sources** PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022.

**Study selection** Randomized controlled trials (RCTs) comparing anti-VEGF with sham, photodynamic therapy (PDT) or PDT combination therapy for patients with myopia CNV were reviewed and selected.

**Data extraction and synthesis** Two reviewers independently conducted data extraction and quality assessment. We used a random-effects model for all analyses. Primary outcomes included best-corrected visual acuity (BCVA) and central foveal thickness. Secondary outcomes included number of patients who gained more than 3 lines in BCVA, number of anti-VEGF injections and ocular adverse events (AEs).

**Results** Seven RCTs involving 1007 patients were included. Compared with sham and PDT treatment, anti-VEGF therapy achieved better BCVA gain of -0.28 logMAR (95% CI:-0.36 to -0.20, P < 0.00001) and -0.14 logMAR (95% CI:-0.17 to -0.10, P < 0.00001), respectively, and no definitive increased risk of ocular AEs were observed in anti-VEGF therapy group. There were no significant differences in the efficacy and safety of anti-VEGF monotherapy compared with PDT combination therapy. The comparison of different anti-VEGF retreatment regimens showed that disease activity criteria resulted in similar visual improvement and required fewer anti-VEGF injections compared to visual acuity stabilization criteria (WMD=0.83, 95% CI: 0.42 to 1.25, P < 0.0001).

**Conclusions** Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment regimen guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections.

#### PROSPERO registration number CRD42021292806.

**Key Words** anti-VEGF; myopia choroidal neovascularization; retreatment regimen; meta-analysis.

# Strengths and limitations of this study

- The major strength of this study was designed to compare different anti-VEGF retreatment regimens and found disease activity criteria may be a more recommended retreatment regimen.
- This meta-analysis described a review protocol that was formally registered on PROSPERO and provided the latest RCTs of anti-VEGF for myopic CNV.
- The number of included studies was relatively small, and some RCTs had small sample size. Further more large and high quality research were needed.
- The heterogeneity in some parameters partly due to inconsistent follow-up times of included RCTs, may affect the overall reliability of the results.

# **INTRODUCTION**

Pathologic myopia is characterized by excessive elongation of the eyeball leading to various degenerative changes in the retina and visual deterioration <sup>1</sup>. Among the complications of pathologic myopia, choroidal neovascularization (CNV) and mechanical rupture of Bruch membrane are the most serious degenerative changes <sup>2</sup>. Pathologic myopia is the second cause of CNV after neovascular age-related macular degeneration (nAMD), approximately 5.2% to 11.3% of pathological myopia patients developing to myopic CNV <sup>3</sup> <sup>4</sup>. Myopic CNV has a higher prevalence in Asian population and most of patients present at 50 years of age or younger rather than old age <sup>5</sup>. Without treatment, the majority of myopic CNV patients will develop a poor visual outcome. A 10 years follow-up study showed that over 95% of myopic CNV patients' visual acuity (VA) reduced to 0.1 or even worse after 5 and 10 years of onset <sup>6</sup>.

Before the use of anti-VEGF therapy in myopic CNV, treatment strategies mainly include laser photocoagulation, verteporfin photodynamic therapy (PDT) and submacular surgery <sup>7</sup>. But the clinical application of these approaches are limited by complications such as myopic CNV recurrence, scarring, atrophy, and choroidal ischemia <sup>8-10</sup>. PDT has been the most widely used treatment for myopic CNV since the Verteporfin in Photodynamic Therapy (VIP) study showed that patient treated with PDT had a better visual outcome compared to placebo over 12 months <sup>11</sup>. However, the 2-year follow up of the VIP trial reported PDT treatment had no statistically significant benefit with a high percentage of reoccurrence of intraretinal fluid <sup>12</sup>. Another study showed the development of chorioretinal atrophy was seen in 83% of PDT treated patient at 5 years <sup>13</sup>. Since anti-vascular endothelial growth factor (anti-VEGF) therapy become available, PDT has fallen out of favour and only considered if anti-VEGF therapy is contraindicated.

VEGF is a proangiogenic cytokine that stimulates the development of CNV and the abnormal increase of intraocular VEGF <sup>14</sup>. Anti-VEGF can bind VEGF receptor to inactivate endogenous VEGF and inhibit the migration and proliferation of vascular

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

endothelial cell, thereby inhibiting neovascularization <sup>15</sup>. The earliest report of intraocular injection of anti-VEGF drugs for myopic CNV was in 2006 and become more and more widely used in recently years <sup>16</sup> <sup>17</sup>. Although previous studies have shown that anti-VEGF therapy resulted in better visual, comparative studies mainly consist of non-RCTs and a small number of RCTs, which limits the strength to support clinical application <sup>18</sup> <sup>19</sup>. Furthermore, despite clinical approval of anti-VEGF therapy for myopia CNV, the optimal retreatment regimen has not been unified <sup>20</sup>.

In recent years, new RCTs about anti-VEGF therapy for myopia CNV have been published and long-term data on efficacy and safety have been accumulated. Most importantly, two large RCTs have been completed to compare the therapeutic effects of different anti-VEGF retreatment regimens <sup>21</sup> <sup>22</sup>. Our objective was to update the latest clinical evidence and to explore a preferred anti-VEGF retreatment regimen for myopic CNV.

## **METHODS**

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline <sup>23</sup>.

## Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

## Data sources and search strategy

The databases of PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022. The meta-analysis protocol was approved and registered in PROSPERO website with a registration number of CRD42021292806. A range of MESH words and free terms regarding CNV, anti-VEGF, ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea), conbercept (Lumitin), RCT were used in all combinations possible to search for relevant articles. The search strategy is provided in the online supplementary

 appendix 1. No language restriction was applied. We also manually searched the reference lists of included studies to identify other potentially eligible articles.

# Eligibility criteria

We included the following published studies if they met the criteria: (1) patients with active myopia CNV (with spherical equivalent  $\geq$  -6.0 dioptres and an axial length  $\geq$  25.0 mm); (2) studies were RCTs that directly compared intravitreal anti-VEGF drugs with sham or PDT or PDT combination therapy, and comparison of different anti-VEGF retreatment regimen also included; (3) studies reported one or more of interest outcomes. Exclusion criteria were employed as follows: (1) patients were previously treated with several drugs; (2) comparative studies between different anti-VEGF drugs, noncomparative studies, animal studies or case reports; (3) unfinished studies or unavailable data.

# Data extraction and quality assessment

Titles and abstracts were independently scanned by two reviewers using the above selection criteria. Disagreements were discussed and if necessary, resolved by a third reviewer. Data were extracted in a prespecified data extraction form. The following data were extracted from the articles included: general data (title, first author, study design, inclusion and exclusion criteria), basic characteristics (age, sex, sample size), intervention groups, follow-up time, primary outcomes (BCVA and central foveal thickness (CFT)) and secondary outcomes (the number of patients who gained more than 3 lines in BCVA, the number of anti-VEGF injection and the number of serious or nonserious ocular adverse events (AEs)). Quality for RCTs was assessed using the Cochrane risk of bias tool <sup>24</sup>.

# Data synthesis and statistical analysis

The meta-analysis was conducted using Review Manager 5.3 supplied by Cochrane Collaboration (Oxford, United Kingdom). The weighted mean difference (WMDs) with 95% confidence interval (CIs) were measured for continuous data, while the risk ratios (RRs) with 95% CIs were measured for dichotomous data. Visual outcome was measured using the Early Treatment Retinopathy study (ETDRS) chart, the data were

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

converted to logarithmic visual acuity (logMAR) for analyses <sup>25</sup> <sup>26</sup>. Heterogeneity between studies was assessed using the I<sup>2</sup> test. I<sup>2</sup> > 50% was defined as the presence of substantial heterogeneity <sup>27</sup>. Due to the possibility of heterogeneity being present between studies, a more conservative version of the random-effects model was applied. A value of p<0.05 was chosen as the significance level for outcome measures.

# RESULTS

# Literature search

In total, 3376 relevant articles were identified initially. After removed 841 duplicates, we screened the remaining 2535 articles and 2497 articles were excluded based on the titles and abstracts. The remaining 38 articles were retrieved for full-text review, and 7 eligible RCTs <sup>21</sup> <sup>22</sup> <sup>28-32</sup> were included for meta-analysis (figure 1). Among the 7 included RCTs, 1 RCT compared anti-VEGF with sham treatment, 4 RCTs compared anti-VEGF with PDT, and 2 RCTs compared anti-VEGF monotherapy with PDT combination therapy. Besides, 2 RCTs compared different anti-VEGF retreatment regimens guided by VA stabilization criteria or disease activity criteria, respectively.

## **Study characteristics**

The basic characteristics of included 7 RCTs are shown in table 1. The study included a total of 1007 participants. The followed-up duration was 12 to 24 months. The mean age ranged from 44.6 to 62.4 years and females accounted for 52.5% to 76.5%. The anti-VEGF treatments used in the included studies were intravitreal bevacizumab (IVB 1.25mg), ranibizumab (IVR 0.5mg) and aflibercept (IVA 2.0mg). The PDT monotherapy received standard fluence PDT (50 J/cm<sup>2</sup>) and the PDT combination therapy received reduced fluence PDT (25 J/cm<sup>2</sup>) in combination with intravitreal anti-VEGF.

For different anti-VEGF retreatment regimens, patients retreatment guided by VA stabilization criteria received anti-VEGF on day 1 and month 1, and thereafter monthly injections were performed when there was a loss of VA (change in BCVA)

 and investigator judgment). Patients retreatment guided by disease activity criteria
received anti-VEGF on day 1, and thereafter monthly injections were performed when
observed disease activity (intraretinal or subretinal fluid assessed by optical coherence
tomography, or active leakage assessed by fluorescein angiography).

 Table 1
 Characteristics of the included seven studies

12 13	Study/	Study	NCT Trial	Patients	Sample Size	Mean Age	Sex	Intervention	Follow-up
14	Year	Design	No.		(Patient)	(Year)	(M/F)	Groups	(Months)
15 16 17 18	MYRROR 2014 <sup>28</sup>	RCT	01249664	Subfoveal or juxtafoveal CNV secondary to high	121	58.2±13.3	29/92	IVA (2.0 mg); Sham (no Drug)	12
18 19 20 21	Parodi 2010 <sup>29</sup>	RCT	None	myopia Juxtafoveal CNV secondary to pathologic myopia	37	49.45	13/24	IVB (1.25 mg); SF PDT (50 J/cm <sup>2</sup> )	24
22 23 24	Moreno 2013 <sup>30</sup>	RCT	00967850	Subfoveal and/or juxtafoveal CNV secondary to pathologic myopia	42	None	None	IVB (1.25 mg); SF PDT (50 J/cm <sup>2</sup> )	24
25 26 <sup>R</sup> 27 28 29 30 31	ADIANCE 2014 <sup>21</sup>	RCT	01217944	Subfoveal or juxtafoveal or extrafoveal CNV secondary to pathologic myopia	276	55.56±13.96	68/209	IVR (0.5 mg): guided by VA stabilization; IVR (0.5 mg): guided by disease activity; SF PDT (50 J/cm <sup>2</sup> )	12 24 24 12 12
34 35 36 37	RILLIANCE 2019 <sup>22</sup>	RCT	01922102	Subfoveal or juxtafoveal or extrafoveal CNV secondary to pathologic myopia	457	51.2±12.7	146/311	IVR (0.5 mg): guided by VA stabilization; IVR (0.5 mg): guided by disease activity; SF PDT (50 J/cm <sup>2</sup> )	12
38 39 40 41	Saviano 2013 <sup>31</sup>	RCT	None	Subfoveal or juxtafoveal CNV secondary to pathologic myopia	34	62.4	8/26	IVB (1.25 mg); IVB (1.25 mg) + RF PDT*	
42 43 44 45 <del>46</del>	Rinaldi 2016 <sup>32</sup>	RCT	01968486	Subfoveal or juxtafoveal CNV secondary to pathologic myopia	40	44.6±4.48	19/21	IVR (0.5 mg); IVR (0.5 mg) + RF PDT (25 J/cm <sup>2</sup> )	12

RCT, randomized controlled trial; NCT, national clinical trial; CNV, choroidal neovascularization; PDT, photodynamic therapy; anti-VEGF, anti-vascular endothelial growth factor; M/F, male/female; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVA, intravitreal aflibercept; VA, visual acuity; SF PDT, standard fluence photodynamic therapy.

## **Risk of bias assessment**

Risk of bias assessment for included RCTs is shown in the online supplementary appendix 2. Two RCTs <sup>21 22</sup> were considered to be at low risk of bias for all domains. Most unclear risk of bias was assigned in domains of selection bias or detection bias <sup>28</sup>

similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

<sup>29 31</sup>. Two RCTs <sup>30 31</sup> were considered to be high risk of bias for performance bias and attrition bias, respectively.

## Anti-VEGF versus sham treatment

MYRROR study <sup>28</sup> compared aflibercept with sham treatment and results were presented at the end of 6-month, as the sham treatment group could receive aflibercept when needed. The results showed that patients in anti-VEGF treatment achieved significant better BCVA (WMD=-0.28 logMA; 95% CI -0.36 to -0.20, p<0.00001; figure 2) and CFT reduction (WMD=-66.80; 95% CI -114.87 to -18.73, p=0.006; figure 3) than sham treatment group. The number of patients who gained more than 3 lines in BCVA was significantly higher in the anti-VEGF treatment than in the sham treatment group (RR= 4.02, 95% CI 1.33 to 12.15, p=0.01; figure 4). The incidence of serious (p=0.55; table 2) and non-serious ocular AEs (p=0.13; table 2) were similar in anti-VEGF and sham treatment group. There were 3 serious ocular AEs (only 1 macular hole in study eye) in anti-VEGF and no event occurred in sham treatment group. The most common non-serious ocular AEs in anti-VEGF treated patients were mild conjunctival hemorrhage, punctate keratitis, eye pain and dry eye, but did not lead to the interruption of treatment.

non-serious ocular adverse events							
Comparison	No. of RCTs	Risk ratio	Р	I <sup>2</sup> (%)	P for		
	(no. of Patients)	(95% CI)			heterogeneity		
The number of anti-VEGF injections							
Anti-VEGF vs PDT	2(74) 31 32	1.30 (1.24,1.37)	0.00001	32	0.23		
combination							
Retreatment criteria: VA	2(587) <sup>21 22</sup>	0.83 (0.42,1.25)	0.0001	0	0.38		
stabilization vs disease activity							
The number of serious ocular adve	The number of serious ocular adverse events						
Anti-VEGF vs Sham treatment	1(121) 28	2.46 (0.13,46.36)	0.55	—	—		
Anti-VEGF vs PDT	4(525) <sup>21</sup> <sup>22</sup> <sup>29</sup> <sup>30</sup>	0.81(0.11,6.10)	0.84	0	0.62		
Retreatment criteria: VA	2(587) <sup>21 22</sup>	1.06 (0.15,7.45)	0.96	0	0.96		
stabilization vs disease activity							
The number of non-serious ocular adverse events							
Anti-VEGF vs Sham treatment	1(121) 28	0.57 (0.28,1.18)	0.13	_	_		

**Table 2** Meta-analysis results of the number of anti-VEGF injections, serious and non-serious ocular adverse events

Anti-VEGF vs PDT	4(525) <sup>21</sup> <sup>22</sup> <sup>29</sup> <sup>30</sup>	1.02(0.77,1.36)	0.88	0	0.90
Anti-VEGF vs PDT	2(74) 31 32	1.57 (0.77,3.22)	0.22	_	_
combination					
Retreatment criteria: VA	2(587) <sup>21 22</sup>	1.04 (0.83,1.31)	0.72	0	0.41
stabilization vs disease activity					

RCT, randomized controlled trial; anti-VEGF, anti-vascular endothelial growth factor; PDT, photodynamic therapy; VA, visual acuity.

# **Anti-VEGF versus PDT**

Four RCTs <sup>21</sup> <sup>22</sup> <sup>29</sup> <sup>30</sup> compared anti-VEGF with PDT treatment. For the RADIANCE and BRILLIANCE study <sup>21</sup> <sup>22</sup>, results were presented at the end of 3-month, as patients in PDT group could receive ranibizumab when needed. A significant increase of BCVA from baseline was observed in both groups. Compared to PDT, the mean improvement of BCVA (WMD=-0.14 logMAR; 95% CI -0.17 to -0.10, p<0.00001, I<sup>2</sup>=68%; figure 2) and reduction of CFT (WMD=-44.32; 95% CI -59.85 to -28.79, p<0.00001, I<sup>2</sup>=20%; figure 3) were superior in anti-VEGF group. And the number of patients who gained more than 3 lines in BCVA was more in anti-VEGF group (RR=2.42; 95% CI 1.68 to 3.50, p<0.00001, I<sup>2</sup>=0%; figure 4), too. Anti-VEGF group recorded 2 serious ocular AEs (1 retinal detachment and 1 retinoschisis) and PDT group recorded 1 endophthalmitis (p=0.84; table 2).The non-serious ocular AEs showed no significant differences between the two groups (p=0.88; table 2) and most frequently reported were conjunctival hemorrhage and punctate keratitis.

# Anti-VEGF monotherapy versus PDT combination therapy

Two small RCTs <sup>31 32</sup> compared anti-VEGF monotherapy with PDT combination therapy. The mean BCVA (WMD=0.07 logMAR; 95% CI -0.00 to 0.14, p=0.06,  $I^2=61\%$ ; figure 2) and CFT (WMD=6.40; 95% CI -20.10 to 32.90, p=0.64; figure 3) were improved both in anti-VEGF monotherapy and PDT combination therapy group, but there were no statistical difference between them. The number of patients who gained more than 3 lines in BCVA (RR=0.92; 95% CI 0.57 to 1.49, p=0.74; figure 3) was similar in both groups, too. Nevertheless, the anti-VEGF injections in PDT combination therapy was statistically fewer than anti-VEGF monotherapy group (WMD=1.30; 95% CI 1.24 to 1.37, p<0.00001, I<sup>2</sup>=32%; table 2). No serious ocular AE was documented and some mild non-serious ocular AEs were observed in both groups, including ocular hyperemia, myodesopsia, conjunctival hemorrhage and eye pain (p=0.22; table 2).

## Anti-VEGF retreatment regimens: VA stabilization criteria versus

## disease activity criteria

 Two RCTs <sup>21</sup> <sup>22</sup> compared the therapeutic effect of different anti-VEGF retreatment regimens. No significant difference in mean BCVA (WMD=-0.00 logMAR; 95% CI -0.04 to 0.03, p=0.91, I<sup>2</sup>=0%; figure 2) and CFT change (WMD=2.31; 95% CI -11.46 to 16.08, p=0.74, I<sup>2</sup>=0%; figure 3). The number of patients who gained more than 3 lines in BCVA got the same results (RR=1.07; 95% CI 0.90 to 1.27, p=0.47, I<sup>2</sup>=0%; figure 4). Interestingly, the number of anti-VEGF injections guided by disease activity criteria was significantly fewer than VA stabilization criteria group (WMD=0.83; 95% CI 0.42 to 1.25, p<0.0001, I<sup>2</sup>=0%; table 2). Safety profile showed no significant difference in patients between the two anti-VEGF retreatment regimens. There were 2 serious ocular AEs, respective 1 retinal detachment in VA stabilization criteria and 1 retinoschisis in disease activity criteria group (p=0.96; table 2). The most frequently reported non-serious ocular AE was conjunctival hemorrhage (p=0.72; table 2).

# DISCUSSION

In this meta-analysis, we evaluated the efficacy and safety of anti-VEGF treatment and compared two different anti-VEGF retreatment regimens. Evidences showed that anti-VEGF was superior to improving VA compared to sham or PDT treatment. Moreover, anti-VEGF monotherapy showed similar visual improvement compared to PDT combination therapy. For different retreatment regimens, anti-VEGF retreatment guided by disease activity criteria could achieve similar visual gain and need fewer anti-VEGF injections compare to VA stabilization criteria. Therefore, this review could provide the latest update on the systematic review of anti-VEGF treatment and provide evidence for optimizing retreatment regimens for myopia CNV.

Myopic CNV was a progressive disease and VA in the sham treatment group became worse than baseline without treatment <sup>21</sup>. The short-term treatment effect of PDT was remarkable, but the long-term effect was poor and the recurrence rate was high <sup>13</sup> <sup>14</sup>. Analysis results indicated that anti-VEGF therapy had a better visual and anatomical improvement than sham or PDT treatment. Moreover, the post hoc analyses of RADIANCE study demonstrated BCVA gain of anti-VEGF therapy was sustained over additional 36 months <sup>33</sup>. There was no significant difference in VA improvement between anti-VEGF monotherapy and PDT combination therapy, but PDT combination therapy needed fewer anti-VEGF injections. However, PDT combination therapy would increase the cost of PDT related treatment, so whether it was more cost-effective treatment needs further evaluation.

For safety estimation, there were no significant differences in the incidence of serious and non-serious ocular AEs between anti-VEGF therapy and other treatments. The most common ocular AEs of anti-VEGF treatment were mild conjunctival hemorrhage and punctate keratitis, which were well tolerated in myopic CNV patients. Although some cases reported that new onset myopic macular retinoschisis (MRS) may be a complication of anti-VEGF intravitreal therapy, only 1 MRS event was reported in MYRROR study, and another study also found there was no association between the new onset of MRS and anti-VEGF therapy <sup>34-36</sup>.

Currently, the guidance and consensus statement recommended anti-VEGF therapy for myopic CNV, but did not point out the definite retreatment regimen <sup>20</sup>. Most clinical research refer to retreatment regimen guided by disease activity criteria (intraretinal or subretinal fluid) or VA stabilization criteria (increased BCVA or blurring or metamorphops), or both <sup>37-40</sup>. The use of different retreatment criteria may affect retreatment rates and the number of anti-VEGF injections. Fewer injections can lead to lower risk of AEs, preferable compliance, and lower cost. Simultaneous monthly measurement of VA stabilization and disease activity to guide anti-VEGF retreatment is more accurate, but it also imposes a considerable economic burden on health systems. Therefore, it is crucial to determine an optimal retreatment regimen, especially for myopic CNV patients in developing countries <sup>41</sup>. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Two multicenter RCTs <sup>21</sup> <sup>22</sup> compared different anti-VEGF retreatment regimens for myopic CNV. The results found that disease activity criteria had similar visual efficacy and safety compared to VA stabilization criteria, but the number of anti-VEGF injections needed was significantly fewer in disease activity criteria. Analyzing the reasons, the anatomical changes that typically precede the actual VA loss, thereby anti-VEGF retreatment guided by disease activity criteria could control disease progression earlier and more sensitive than VA stabilization criteria <sup>42</sup>. VA stabilization retreatment criteria required more frequent injections of anti-VEGF, which means higher treatment costs and increases the possibility of AEs. Thus, anti-VEGF retreatment guided by disease activity criteria may be a more preferred option for the treatment of myopic CNV.

However, there were some limitations in this meta-analysis. The number of included studies was relatively small, and some RCTs had small sample size. The large degree of heterogeneity in some parameters partly due to inconsistent follow-up times of included RCTs. Besides, the followed-up duration was limited to 12-24 months, which were too short to catch more significant differences in progression of anti-VEGF therapy. Therefore, large, high quality and long-term clinical evidence is needed to support our view in the future.

# **CONCLUSIONS**

The meta-analysis suggests that anti-VEGF is effective and well tolerated for improving VA in patients with myopic CNV comparing with sham, PDT and PDT combination therapy. Compared with VA stabilization criteria, anti-VEGF retreatment guided by disease activity criteria can produce similar therapeutic efficacy and reduce anti-VEGF injections, which may be a more recommended retreatment regimen for myopic CNV patients.

**Contributors** LD: reviewed literature, data collection, prepared and revised the manuscript. GL: supervision, data collection and data analysis. ZS: data collection and revised the manuscript. XC: data collection and data analysis. JB: data analysis and critical appraisal. CZ: supervision, critical appraisal and revised the manuscript.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

**Ethics approval** This study was conducted using published data and did not involve human participants directly. Therefore, this work was exempt of ethical review by Ethics Committee of Beijing Tongren Hospital Affiliated to Capital Medical University.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

## REFERENCES

  Flitcroft DI, He M, Jonas JB, *et al.* IMI-defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. *Invest Ophthalmol Vis Sci* 2019; 60:M20-M30.

**BMJ** Open

- 2 Ng DSC, Ho M, Iu LPL, *et al.* Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. *Expert Opin Drug Saf* 2022; 21:43-54.
- 3 Wong TY, Ohno-Matsui K, Leveziel N, *et al.* Myopic choroidal neovascularisation: current concepts and update on clinical management. *Br J Ophthalmol* 2015; 99:289-96.
- 4 Wong TY, Ferreira A, Hughes R, *et al.* Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. *Am J Ophthalmol* 2014; 157:9-25.e12.
- 5 Cohen SY, Laroche A, Leguen Y, *et al.* Etiology of choroidal neovascularization in young patients. *Ophthalmology* 1996; 103:1241-4.
- 6 Yoshida T, Ohno-Matsui K, Yasuzumi K, *et al.* Myopic choroidal neovascularization: a 10-year follow-up. *Ophthalmology* 2003; 110:1297-305.
- 7 Ohno-Matsui K, Ikuno Y, Lai TYY, *et al.* Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. *Prog Retin Eye Res* 2018; 63:92-106.
- 8 Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. *Cochrane Database Syst Rev* 2005; (4):CD004765.
- 9 Hayashi K, Ohno-Matsui K, Shimada N, *et al.* Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. *Am J Ophthalmol* 2011; 151:137-147.
- 10 Ng DSC, Fung NSK, Yip FLT, *et al.* Ranibizumab for myopic choroidal neovascularization. *Expert Opin Biol Ther* 2020; 20:1385-1393.
- 11 Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin.
  1-year results of a randomized clinical trial--VIP report no. 1. *Ophthalmology*

#### BMJ Open

 2001; 108:841-52.

- 12 Blinder KJ, Blumenkranz MS, Bressler NM, *et al.* Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. *Ophthalmology* 2003; 110:667-73.
- 13 Giansanti F, Virgili G, Donati MC, *et al.* Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. *Retina* 2012; 32:1547-52.
- 14 Chan WM, Lai TY, Chan KP, *et al.* Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. *Retina* 2008; 28:1308-13.
- 15 Hu Q, Li H, Du Y, He J. Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2019; 98:e14905.
- 16 Laud K, Spaide RF, Freund KB, *et al.* Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. *Retina* 2006; 26:960-3.
- 17 Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. *Retina* 2006; 26:1093-4.
- 18 Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. *Retina* 2013; 33:1375-92.
- 19 Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 2016; 12:CD011160.
- 20 Cheung CMG, Arnold JJ, Holz FG, *et al.* Myopic choroidal neovascularization: review, guidance, and consensus statement on management. *Ophthalmology* 2017; 124:1690-1711.
- 21 Wolf S, Balciuniene VJ, Laganovska G, *et al.* RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization 16

secondary to pathologic myopia. Ophthalmology 2014; 121:682-92.e2.

- 22 Chen Y, Sharma T, Li X, *et al.* Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. *Retina* 2019; 39:1985-1994.
- 23 Page MJ, Moher D, Bossuyt PM, *et al.* PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021; 29:372:n160.
- 24 Higgins JP, Altman DG, Gøtzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
- 25 Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. *Retina* 2010; 30:1046-50.
- 26 Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;
   30:287-90.
- 27 Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003; 327:557-60.
- 28 Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 2015; 122:1220-7.
- 29 Parodi MB, Iacono P, Papayannis A, *et al.* Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. *Arch Ophthalmol* 2010; 128:437-42.
- 30 Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, et al. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophthalmology 2013; 120:1510-1.e1.
- 31 Saviano S, Piermarocchi R, Leon PE, *et al.* Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. *Int J Ophthalmol* 2014; 7:335-9.
- 32 Rinaldi M, Semeraro F, Chiosi F, *et al*. Reduced-fluence verteporfin photodynamic

#### **BMJ** Open

therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. *Graefes Arch Clin Exp Ophthalmol* 2017; 255:529-539.

- 33 Tan NW, Ohno-Matsui K, Koh HJ, *et al.* Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the RADIANCE study. *Retina* 2018; 38:2228-2238.
- 34 Tufan HA, Gencer B, Kara S. Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation. *Clin Exp Optom* 2014; 97:178-80.
- 35 Lai TY, Luk FO, Lee GK, *et al.* Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. *Eye (Lond)* 2012; 26:1004-11.
- 36 Zhou Y, Yang S, Yuan Y, *et al.* Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after conbercept therapy: a post-hoc analysis. *Eye (Lond)* 2020; 34:523-529.
- 37 Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. *Ophthalmology* 2013; 120: 1944-1945.
- 38 Iacono P, Battaglia Parodi M, *et al.* Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization. *Retina* 2017; 37:1931-1941.
- 39 Li S, Ding X, Sun L, *et al.* Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. *Clin Exp Ophthalmol* 2019; 47:250-258.
- 40 Ng DS, Kwok AK, Tong JM, *et al.* Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. *Retina* 2015; 35:2457-68.
- 41 Parikh R, Pirakitikulr N, Chhablani J, *et al.* A multinational comparison of anti-Vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific. *Ophthalmol Retina* 2019; 3(1):16-26.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

42 Hoerster R, Muether PS, Hermann MM, *et al.* Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. *Br J Ophthalmol* 2011; 95:1424-6.

#### **Figure legends**

Figure 1 Flow diagram of study selection process that was conducted in PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov.

Figure 2 Forest plot of studies examining the mean change in BCVA (logMAR).

Figure 3 Forest plot of studies examining the number of patients who gained more than 3 lines in BCVA.

Figure 4 Forest plot of studies examining the mean change in CFT.




Figure 1 Flow diagram of study selection process that was conducted in PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov.

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4 5	
6 7 8 9 10 11	
12 13 14 15 16	
17 18 19 20 21 22	
23 24 25 26 27 28	
29 30 31 32 33 34	
35 36 37 38 39	
40 41 42 43 44 45	
46 47 48 49 50	
51 52 53 54 55	
56 57 58 59	

60





Figure 2 Forest plot of studies examining the mean change in BCVA (logMAR).

	Favours	(experime	intal]		Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
2.1.1 Anti-VEGF vs Sh	am control								
MYRROR 2014	-80.7	83.7	90	-13.9	127.4	31	100.0%	-66.80 [-114.87, -18.73]	
Subtotal (95% CI)			90			31	100.0%	-66.80 [-114.87, -18.73]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z= 2.72 (P	= 0.006)							
2.1.2 Anti-VEGF vs PD	т								
BRILLIANCE 2019	-71.2	81.28	184	-29.1	75.57	91	63.6%	-42.10 [-61.57, -22.63]	
Moreno 2013	-50.4	65.72	22	-25.5	64.42	20	15.5%	-24.90 [-64.29, 14.49]	
RADANCE 2014		110.67	116		103.85	55	20.8%		
Subtotal (95% CI)	11.0	110.01	322		100.00	166	100.0%		•
Heterogeneity: Chi <sup>2</sup> =	2 48 df = 2	(P = 0.29)	F = 209	*					
Test for overall effect:									
2.1.3 Anti-VEGF vs Co	mbind ther	apv							
Rinaldi 2016	-85	41.7	20	-91.4	43.8	20	100.0%	6.40 [-20.10, 32.90]	_
Subtotal (95% CI)			20			20	100.0%	6.40 [-20.10, 32.90]	<b></b>
Heterogeneity: Not ap	plicable								
Test for overall effect:		= 0.64)							
2.1.4 Retreatment cri	teria: VA st	abilizatio	n vs Dise	ease ac	tivity				
BRILLIANCE 2019	-79.4	71.39	182			184	72.4%	1.40 [-14.78, 17.58]	
RADANCE 2014	-66.6	84.98	105		113.04	116	27.6%	4.70 [-21.52, 30.92]	
Subtotal (95% CI)	5010		287			300	100.0%	2.31 [-11.46, 16.08]	+
Heterogeneity: Chi <sup>2</sup> =	0.04. df = 1	(P = 0.83)	: I <sup>2</sup> = 0%						
Test for overall effect:									
									Y 10 Y 10
									-100 -50 0 50 100

Figure 3 Forest plot of studies examining the number of patients who gained more than 3 lines in BCVA.

te/about/guidelines.xhtml



Study or Subgroup

MYRROR 2014

Total events

Moreno 2013

RADANCE 2014

Subtotal (95% CI)

Parodi 2010

Total events

Rinaldi 2016

Total events

Subtotal (95% CI)

**BRILLIANCE 2019** 

RADANCE 2014

Subtotal (95% CI)

Total events

Heterogeneity: Not applicable

Subtotal (95% CI)

Heterogeneity: Not applicable

3.1.2 Anti-VEGF vs PDT BRILLIANCE 2019

Page 25 of 53	BMJ Open
1 2 3 4 5	Search strategy
6 7 8 9	1. PubMed search strategy
10 11	Date: From inception to 31 July 2022
12 13 14	Search strategy:
15 16 17	#1 AntiVEGF [All Fields]
18 19 20	#2 Anti-VEGF [All Fields]
21 22 23	#3 "Vascular Endothelial Growth Factors"[Mesh Terms] #4 "Vascular Endothelial Growth Factors"[All Fields]
24 25 26	#5 VEGFs [All Fields]
27 28 29	#6 ranibizumab [MeSH Terms]
30 31 32	#7 ranibizumab [All Fields]
33 34 35	#8 rhumab [All Fields]
36 37 38	#9 bevacizumab [MeSH Terms]
39 40 41	<pre>#10 bevacizumab [All Fields] #11 Avastin [All Fields]</pre>
42 43 44	<ul> <li>#8 rhumab [All Fields]</li> <li>#9 bevacizumab [MeSH Terms]</li> <li>#10 bevacizumab [All Fields]</li> <li>#11 Avastin [All Fields]</li> <li>#12 altuzan [All Fields]</li> </ul>
45 46 47	#13 vasi [All Fields]
48 49 50	#14 aflibercept [All Fields]
51 52 53	#15 aflibercept[Supplementary Concept]
54 55 56	#16 eylea [All Fields]
57 58 59	#17 "VEGF Trap" [All Fields]
60	#18 Zaltrap [All Fields]

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- #19 "AVE 0005" [All Fields]
- #20 conbercept [All Fields]
- #21 KH902 [All Fields]
- #22 "KH902 fusion protein" [Supplementary Concept]
- #23 Brolucizumab [Supplementary Concept]
- #24 Brolucizumab [All Fields]
- #25 Beovu [All Fields]
- #26 RTH258 [All Fields]
- #27 ESBA1008 [All Fields]

#28 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR

#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21

OR #22 OR #23 OR #24 OR #25 OR #26 OR #27

- #29 "Choroidal Neovascularization" [MeSH Terms]
- #30 "CNV" [All Fields]
- #31 mCNV [All Fields]
- #32 Choroid AND Neovascularization \* [All Fields]
- #33 Choroidal AND Neovascularization \*[All Fields]
- #34 #29 OR #30 OR #31 OR #32 OR #33
- #35 Controlled Clinical Trial [Publication Type]
- #36 Randomized Controlled Trial [Publication Type]
- #37 "Controlled Clinical Trial" [All Fields]
- #38 "Randomized Controlled Trial" [All Fields]

<ul> <li>#39 "Randomized Controlled Trial" [All Fields]</li> <li>#40 RCT [All Fields]</li> <li>#41 random*[All Fields]</li> <li>#42 trial [All Fields]</li> <li>#43 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42</li> <li>#44 #28 AND #34 AND #43</li> <li>Items: 920</li> </ul>	
50 51 52 53	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## 2. EMBASE search strategy

Date: From inception to 31 July 2022

Search strategy:

#1 AntiVEGF [All Fields]

#2 Anti-VEGF [All Fields]

#3 'vasculotropin inhibitor'/exp

#4 vasculotropin [All Fields]

cors' [A. #5 'Vascular Endothelial Growth Factors' [All Fields]

#6 VEGFs [All Fields]

#7 'ranibizumab'/exp

#8 ranibizumab [All Fields]

#9 lucenti [All Fields]

#10 rhumab [All Fields]

#11 'bevacizumab'/exp

#12 bevacizumab [All Fields]

#13 Avastin [All Fields]

#14 altuzan [All Fields]

#15 vasi [All Fields]

#16 aflibercept [All Fields]

#17 'aflibercept'/exp

#18 eylea [All Fields]

#19 'VEGF Trap' [All Fields]

1	
2 3	
4	#20 Zaltrap [All Fields]
5	
6	
7	#21 'AVE 0005' [All Fields]
8	
9	#22 'conbercept'/exp
10 11	
12	#23 KH902 [All Fields]
13	
14	#24 'Prolucizumah'/own
15	#24 'Brolucizumab'/exp
16	
17	#25 Brolucizumab [All Fields]
18 19	
20	#26 Beovu [All Fields]
21	
22	#27 RTH258 [All Fields]
23	
24	#20 ECD A 1000 [ A 1] E: 14-1
25	#28 ESBA1008 [All Fields]
26 27	
28	#29 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
29	
30	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
31	
32	OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28
33 34	
35	#30 'Choroidal Neovascularization'/exp
36	#50 Choroldal Neovascularization/exp
37	
38	#31 CNV [All Fields]
39	
40 41	#32 mCNV [All Fields]
42	#32 mCNV [All Fields] #33 (Choroid AND Neovascularization*) [All Fields]
43	#33 (Choroid AND Neovascularization*) [All Fields]
44	
45	#34 (Choroidal AND Neovascularization*) [All Fields]
46	
47 48	1125 1120 OD 1121 OD 1122 OD 1124
49	#35 #30 OR #31 OR #32 OR #33 OR #34
50	
51	#36 'controlled clinical trial'/exp
52	
53	#37 'randomized controlled trial'/exp
54 55	-
56	#38 "Controlled Clinical Trial" [All Fields]
57	
58	#39 "Randomized Controlled Trial" [All Fields]
59	$\pi s s$ Randonnized Controlled That [All Fields]
60	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#40 RCT [All Fields]

#41 random\* [All Fields]

#42 trial [All Fields]

#43 #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42

AND #-. #44 #29 AND #35 AND #43

Items: 1754

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5	3. The Cochrane Library search strategy
6 7 8	Date: From inception to 31 July 2022
9 10 11	Search strategy:
12 13	Search term: [Title Abstract Keyword]
14 15 16	#1 AntiVEGF
17 18 19	#2 Anti-VEGF
20 21	#3 "Vascular Endothelial Growth Factors"
22 23 24	#4 VEGFs
25 26 27	#5 ranibizumab
28 29	#6 lucenti
30 31 32	#4 VEGFs #5 ranibizumab #6 lucenti #7 rhumab #8 bevacizumab #9 Avastin
33 34 35	#8 bevacizumab
36 37	
38 39 40	#10 altuzan
41 42 43	#11 vasi #12 aflibercept
44 45	#12 aflibercept
46 47 48	#13 eylea
49 50 51	#14 "VEGF Trap"
52 53	#15 Zaltrap
54 55 56	#16 "AVE 0005"
57 58 59	#17 conbercept
60	#18 KH902

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#19 Beovu

#20 Brolucizumab

#21 RTH258

#22 ESBA1008

#23 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR

#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21

OR #22

#24 "Choroidal Neovascularization"

#25 CNV

#26 mCNV

#27 (Choroid AND Neovascularization\*)

#28 (Choroidal AND Neovascularization\*)

#29 #24 OR #25 OR #26 OR #27 OR #28

#30 "Controlled Clinical Trial"

#31 "Randomized Controlled Trial"

#32 RCT

#33 random\*

#34 trial

#35 #30 OR #31 OR #32 OR #33 OR #34

#36 #23 AND #29 AND #35

Items: 654

## 4. Clinicaltrial.gov search strategy

Date: From inception to 31 July 2022

Condition or disease: Choroidal Neovascularization

Other terms: AntiVEGF OR Anti-VEGF OR "Vascular Endothelial Growth Factors" OR VEGFs OR ranibizumab OR lucenti OR rhumab OR bevacizumab OR Avastin OR altuzan OR vasi OR aflibercept OR eylea OR "VEGF Trap" OR Zaltrap OR "AVE 0005" OR conbercept OR KH902 OR Brolucizumab OR Beovu OR RTH258 OR ESBA1008

reliez oni

- Study type: Interventional Studies (Clinical Trials)
- Study Results: Studies With Results
- Status: Recruitment: Completed

Items: 44

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Risk of bias assessment for included studies using Cochrane Collaboration's Tool.

	1					
Bias	Authors' judgement	Support for judgement				
Random sequence	Unclear risk	Quote: "MYRROR was an				
generation (selection bias)		international, phase III,				
		multicenter, randomized,				
	5	double-masked, sham-controlled				
		study.				
		Eligible patients were randomized				
	0	in a 3:1 ratio to receive intravitreal				
	5	aflibercept or sham control				
		(stratified by country). "				
		The trial was described as				
		randomised, but the method of				
		sequence generation was not				
		specified, we assessed as "				
		Unclear risk ".				
Allocation concealment	Unclear risk	Not reported				
(selection bias)						
Blinding of participants	Low risk	Quote: "MYRROR was an				

# **1.** Risk of bias assessment for MYRROR (2014)<sup>1</sup>

and personnel		international, phase III,
(performance bias) All		multicenter, randomized,
outcomes		double-masked, sham-controlled
		study."
Blinding of outcome	Low risk	Quote: "MYRROR was an
assessment (detection		international, phase III,
bias)	4	multicenter, randomized,
All outcomes	R	double-masked, sham-controlled
		study."
Incomplete outcome data	Low risk	Quote: "In total, 122 patients were
(attrition bias) All	Ľ,	randomized, of whom 91 received
outcomes	(	intravitreal aflibercept 2.0 mg and
		31 received sham; 122 patients
		were included in the safety set. In
		the full analysis set, 121 patients
		were included (90 patients
		received intravitreal aflibercept 2.0
		mg and 31 received sham). "
		Quote: "According to participant
		flow data on ClinicalTrials.gov, 5
		participants were withdrawn from

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2	
3 4	
5	
6 7	
7 8	
9	
10 11	
12	
13	
14 15	
16	
16 17 18	
18 19	
20	
21 22	
23	
24 25	
25 26	
27	
28 29	
30	
31	
32 33	
34	
35 36	
37	
38	
39 40	
41	
42 43	
44	
45	
46 47	
48	
49 50	
51	
52	
53 54	
55	
56 57	
57 58	
59	
60	

1

		the study and 1 participant did not
		complete visits to week 48 due to
		adverse events, both in the
		aflibercept group. However, only 1
		participant failed to fulfil
		requirements of full analysis set
Ö,		after randomisation. "
Selective reporting	g Low risk	All prespecified outcomes were
(reporting bias)	0	reported.
Other bias	Low risk	No other bias identified.

1. Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology 2015; 122:1220-7.

### 2. Risk of bias assessment for Parodi et al (2010)<sup>2</sup>

Bias	Authors'	Support for judgement
	judgement	1
Random sequence	Low risk	Quote: " Each patient was randomly
generation (selection bias)		allocated to 1 of the 3 treatment
		groups through a
		computer-generated number. "
Allocation concealment	Unclear risk	Not reported

(selection bias)		
Blinding of participants	Unclear risk	Not reported
and personnel		
(performance bias) All		
outcomes		
Blinding of outcome	Low risk	Quote: "At each schedule
assessment (detection		examination, a complet
bias)	5	ophthalmological assessment wa
All outcomes	0	carried out by an investigator wh
	C.	had had no previous contact wit
	6	the subject and was unaware of th
	2	treatment previousl
		administered. "
Incomplete outcome data	Low risk	Quote: "Fifty-four patients affecte
(attrition bias) All		by juxtafoveal CNV in pathologi
outcomes		myopia were recruited; 4 patient
		were excluded because they coul
		not attend the schedule
		examinations; 3 patients were no
		recruited because they were affecte
		by media opacity. "
Selective reporting	Low risk	All prespecified outcomes wer

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

2. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128:437-42.

## 3. Risk of bias assessment for Moreno et al (2013)<sup>3,4</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "The randomisation was
generation (selection bias)		done by the promotor and was
	(O)	provided by the IOBA."
	4	Quote: "We performed a
	C	multicenter prospective study on
		55 highly myopic eyes from 55
		patients with CNV who were
		randomized to PDT (Group 1) or
		intravitreal bevacizumab (IVB)
		(Group 2)."
Allocation concealment	Low risk	Quote: "The randomisation was
(selection bias)		done by the promotor and was
		provided by the IOBA."

Blinding of participants	Low risk	Quote: "The study was doubled
and personnel		masked: (the follow-up physiciar
(performance bias) All		and the optometrist) and the
outcomes		patient were masked."
Blinding of outcome	Low risk	Quote: "The study was doubled
assessment (detection		masked: (the follow-up physiciar
bias)		and the optometrist) and the
All outcomes	5	patient were masked."
Incomplete outcome data	High risk	Quote: "Twenty-four eyes in group
(attrition bias) All	9	1 (86%) and 25 eyes in group 2
outcomes		(92.6%) completed 1 year of
	2	follow-up and 20 eyes in group 1
	(	(71.4%) and 22 eyes in group 2
		(78.6%) completed 2 years o
		follow-up."
		The loss to follow-up was $> 20\%$
		at 2 years and no reason was
		reported.
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

3. Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, et al. Intravitreal bevacizumab in

myopic neovascular membranes: 24-month results. Ophthalmology 2013; 120:1510-1.e1.

4. Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 2016; 12:CD011160.

#### 4. Risk of bias assessment for RADIANCE (2014)<sup>5</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "A randomization list was
generation (selection bias)	8	produced by Novartis Drug Supply
		Management using a validated
	0	system that automates the random
	5	assignment of treatment groups to
		randomization numbers in the
		specified ratio."
Allocation concealment	Low risk	Quote: "At enrollment, patients
(selection bias)		received the lowest available
		randomization number that then
		assigned them in a 2:2:1 ratio to 1
		of the 3 treatment groups."
Blinding of participants	Low risk	Quote: "Due to the different
and personnel		appearances and routes of

(performance bias) All	adr	ministration between the
outcomes	trea	atments, all patients receive
	eitl	her sham injection or PDT sha
	in	conjunction with the stud
	trea	atment. The PDT sha
	сог	nsisted of intravenous injection
Ö.	of	5% dextrose solution follows
	by	light application of PDT. "
~	Qu	ote: "The treating investigat
	wa	s unmasked and administere
	the	randomized study medication
	per	the protocol; however, the
	we	re not involved in any oth
	asp	pects of the study and could n
	cor	nmunicate details of th
	trea	atment."
Blinding of outcome	Low risk Qu	ote: "To ensure masking,
assessment (detection	inv	restigators were involved
bias)	eac	ch study center. All stud
All outcomes	ass	essments were made by th
	eva	aluating investigator, V
	ass	essor, or other site personn

		who were masked to the treatment assignment. "
Incomplete outcome data	Low risk	Quote: "6(5.7%) patients
(attrition bias) All		discontinued from the study:
outcomes		1(0.9%) unsatisfactory therapeutic
		effect; 1(0.9%) subject withdrew
O,		consent; 3(2.8%) lost to follow-up;
	5	1(0.9%) protocol deviation.
	0	4(3.4%) patients discontinued
	C	from the study: 2(1.7%) subject
	< C	withdrew consent; 1(0.9%) lost to
	2	follow-up; 1(0.9%) protocol
	6	deviation. "
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

5. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121:682-92.e2.

#### 5. Risk of bias assessment for BRILLIANCE (2019)<sup>6</sup>

Page 43 of 53

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "Eligible patients were
generation (selection bias)		randomized 2:2:1 to one of three
		treatment arms using an interactive
		response technology system (see
		Figure, Supplemental Digita
		Content 3
	5	http://links.lww.com/IAE/A901,
	9	which shows treatment schedule
	2	and study design)."
Allocation concealment	Low risk	Quote: "Eligible patients were
(selection bias)	Ľ,	randomized 2:2:1 to one of three
	0	treatment arms using an interactive
		response technology system (see
		Figure, Supplemental Digita
		Content 3
		http://links.lww.com/IAE/A901,
		which shows treatment schedule
		and study design). "
Blinding of participants	Low risk	Quote: "BRILLIANCE was a
and personnel		12-month, Phase III, randomized
(performance bias) All		double-masked, multicenter

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

outcomes		active-controlled clinical trial."
		Quote: "For masking purpose,
		sham ranibizumab or sham vPDT
		was applied."
		Quote: "All patients were masked
		to the study treatment."
Blinding of outcome	Low risk	Quote: "In addition, to fulfill the
assessment (detection	5	masking, there were at least two
bias)	0	investigators involved into the
All outcomes	C.	study: masked (assessing)
	6	investigator performing all
	Ľ,	assessments and capturing data;
	(	and an unmasked (treating)
		investigator administering the
		randomized study treatment when
		needed according to the protocol."
Incomplete outcome data	Low risk	Quote: "9(4.9%) patients
(attrition bias) All		discontinued from the study in
outcomes		group 1: 1(0.5%) adverse event;
		7(3.8%) subject withdrew consent;
		1(0.5%) lost to follow-up."
		Quote: "9(4.9%) patients

		discontinued from the study in
		group 2: 2(1.1%) adverse event;
		3(1.6%) subject withdrew consent;
		2(1.1%) administrative problems;
		2(1.1%) physician's decision."
		Quote: "8(8.8%) patients
O,		discontinued from the study in
	5	group 3: 7(7.7%) subject withdrew
	0	consent; 1(1.1%) physician's
	2	decision."
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)	Ľ,	reported.
Other bias	Low risk	No other bias identified.

6. Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. Retina 2019; 39:1985-1994.

#### 6. Risk of bias assessment for Saviano et al (2013)<sup>7</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Unclear risk	Quote: "Thirty-four patients were
generation (selection bias)		included in the study and then
		randomized into two different

		treatment groups." The trial was described as randomised, but the method of sequence generation was not specified, we assessed as " Unclear risk " .
Allocation concealment	Unclear risk	Not reported
(selection bias)	5	
Blinding of participants	Unclear risk	Not reported
and personnel		
(performance bias) All outcomes	(CL	•
Blinding of outcome	Unclear risk	Not reported
assessment (detection		2
bias)		0
All outcomes		
Incomplete outcome data	Low risk	No loss to follow-up.
(attrition bias) All		
outcomes		
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

7. Saviano S, Piermarocchi R, Leon PE, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study. Int J Ophthalmol 2014; 7:335-9.

#### 7. Risk of bias assessment for Rinaldi et al (2016)<sup>8</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "Randomization was
generation (selection bias)	5	performed using
	0	computer-generated random
		numbers: each number
	Ó.	corresponded to a type of
	5	treatment."
Allocation concealment	Low risk	Quote: "Randomization was
(selection bias)		performed using
		computer-generated random
		numbers: each number
		corresponded to a type of
		treatment."
Blinding of participants	High risk	Quote: "The study was a
and personnel		prospective, comparative,
(performance bias) All		interventional, randomized,
outcomes		openlabel clinical trial."

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
3
4
5
5 4 5 6 7 8 9 10 11
6
7
Q
0
9
10
11
12
13
14
12 13 14 15
15
16
17
10
14         14         15         16         17         18         19         20         21         22         23         24         25         26         27         28         29         30         31         32         33         34         35         36         37         38
19
20
21
21
22
23
24
24
25
26
27
27
28
29
20
50
31
32
22
55
34
35
36
50
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
50
59
60

60


1

Blinding of outcome	High risk	Quote: "The study was a
assessment (detection		prospective, comparative,
bias)		interventional, randomized,
All outcomes		openlabel clinical trial."
Incomplete outcome data	Low risk	Quote: "All patients completed the
(attrition bias) All		follow-up at 48 weeks."
outcomes		
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)	e	reported.
Other bias	Low risk	No other bias identified.

8. Rinaldi M, Semeraro F, Chiosi F, et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2017; 255:529-539.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# Reporting checklist for systematic review (with or without a meta-analysis).

Based on the PRISMA guidelines.

### Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMAreporting guidelines, and cite them as:

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

33 34				Page <sub>∃</sub>
35 36 37 38			Reporting Item	Number
	Title			, Al trair
39 40 41	Title	<u>#1</u>	Identify the report as a systematic review	ling, an
42 43	Abstract			d sim
44 45 46 47	Abstract	<u>#2</u>	Report an abstract addressing each item in the PRISMA 2020 for Abstracts checklist	Al training, and similar technologies. 2
48 49	Introduction			logies.
50 51 52 53	Background/rationale	<u>#3</u>	Describe the rationale for the review in the context of existing knowledge	4,5
53 54 55 56 57 58 59 60	Objectives	<u>#4</u>	Provide an explicit statement of the objective(s) or question(s) the review addresses	5
	Methods Fo	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Eligibility criteria	<u>#5</u>	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses
4 5 7 8 9 10	Information sources	<u>#6</u>	Specify all databases, registers, websites, organisations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted
11 12 13 14 15	Search strategy	<u>#7</u>	Present the full search strategies for all databases, registers, and websites, including any filters and limits used
16 17 18 19 20 21 22 23 24 25	Selection process	<u>#8</u>	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and, if applicable, details of automation tools used in the process
26 27 28 29 30 31 32 33 4 35 36 37 38 39 40 41 42 43 44 50 51 52 53 45 56 57 58 960	Data collection process	<u>#9</u>	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and, if applicable, details of automation tools used in the process
	Data items	<u>#10a</u>	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (for example, for all measures, time points, analyses), and, if not, the methods used to decide which results to collect
	Study risk of bias assessment	<u>#11</u>	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and, if applicable, details of automation tools used in the process
	Effect measures	<u>#12</u>	Specify for each outcome the effect measure(s) (such as risk ratio, mean difference) used in the synthesis or presentation of results
	Synthesis methods	#13a or peer rev	Describe the processes used to decide which studies view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

5,6

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. 6 6 6

#### BMJ Open

1 2 3 4			were eligible for each synthesis (such as tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5))
5 6 7 8 9 10 11 12 13	Synthesis methods	<u>#13b</u>	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics or data conversions
	Synthesis methods	<u>#13c</u>	Describe any methods used to tabulate or visually display results of individual studies and syntheses
14 15 16 17 18 19 20 21	Synthesis methods	<u>#13d</u>	Describe any methods used to synthesise results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used
22 23 24 25 26 27	Synthesis methods	<u>#13e</u>	Describe any methods used to explore possible causes of heterogeneity among study results (such as subgroup analysis, meta-regression)
28 29 30 31	Synthesis methods	<u>#13f</u>	Describe any sensitivity analyses conducted to assess robustness of the synthesised results
32 33 34 35 36	Reporting bias assessment	<u>#14</u>	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases)
37 38 39 40	Certainty assessment	<u>#15</u>	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome
40 41 42 43 44 45 46 47 48	Data items	<u>#10b</u>	List and define all other variables for which data were sought (such as participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information
49 50	Results		
51 52 53 54 55 56 57 58 59	Study selection	<u>#16a</u>	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram (http://www.prisma- statement.org/PRISMAStatement/FlowDiagram)
60	Fo	r peer rev	iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5	Study selection	<u>#16b</u>	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded	BMJ Open: first
6 7	Study characteristics	<u>#17</u>	Cite each included study and present its characteristics	7 bublis
8 9 10 11 12 13 14 15 16 17 18 19	Risk of bias in studies	<u>#18</u>	Present assessments of risk of bias for each included study	bed as 10. 8 Prot
	Results of individual studies	<u>#19</u>	For all outcomes, present for each study (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (such as confidence/credible interval), ideally using structured tables or plots	BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July Ens 7 7 8 Protected by copyright, including for uses 11 8-1 8-1 8-1 8-1
20 21 22 23 24 25	Results of syntheses	<u>#20a</u>	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies	July Ens uses
25 26 27 28 29 30 31 32 33 34 35 36 37	Results of syntheses	<u>#20b</u>	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (such as confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect	2023. Downloaded from eignement Superieur (A related to text and data -11 8-12 8-11
	Results of syntheses	<u>#20c</u>	Present results of all investigations of possible causes of heterogeneity among study results	8-11 g, AI
38 39 40 41	Results of syntheses	<u>#20d</u>	Present results of all sensitivity analyses conducted to assess the robustness of the synthesised results	supplementaining 2.9 au
41 42 43 44 45 46	Risk of reporting biases in syntheses	<u>#21</u>	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed	g, Al training, and similar technologies. 11 supplements 12 supplement 8-110 8-11
47 48 49 50	Certainty of evidence	<u>#22</u>	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed	nologies. 8-11gies.
50 51 52 53 54 55 56	Discussion			gence
	Results in context	<u>#23a</u>	Provide a general interpretation of the results in the context of other evidence	Bibliographique de l
57 58	Limitations of	<u>#23b</u>	Discuss any limitations of the evidence included in the	13 13
59 60	Fo	r peer rev	iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	de I

			BMJ Open	Page 54 of 53
1	included studies		review	BMJ
2 3 4 5	Limitations of the review methods	<u>#23c</u>	Discuss any limitations of the review processes used	n/a Open: first
6 7 8 9	Implications	<u>#23d</u>	Discuss implications of the results for practice, policy, and future research	13 13
10 11	Other information			as 10.1 Prote
12 13 14 15 16	Registration and protocol	<u>#24a</u>	Provide registration information for the review, including register name and registration number, or state that the review was not registered	BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July Ens /a n/a 13 Protected by copyright, including for uses n/a 13 n/a
17 18 19 20	Registration and protocol	<u>#24b</u>	Indicate where the review protocol can be accessed, or state that a protocol was not prepared	022-06792 ght, incluc
21 22 23 24	Registration and protocol	<u>#24c</u>	Describe and explain any amendments to information provided at registration or in the protocol	1 on 20 July ling for uses n/a
24 25 26 27 28 29	Support	<u>#25</u>	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review	2023. Downl eignement S related to te 1
30 31 32	Competing interests	<u>#26</u>	Declare any competing interests of review authors	oaded fi xt and c 14
32 33 34 35 36 37 38 39 40	Availability of data, code, and other materials	<u>#27</u>	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review	from http://bmjopen.bmj.com/ on June ur (ABES) . data mining, Al training, and similar te 4 1
41 42	Notes:			and si
43 44 45	20d: supplement	2		on Jun milar t
46 47 48 49 50 51 52 53 54 55 56 57 58	Attribution Licens	se CC-BN	ISMA checklist is distributed under the terms of the Creative Con . This checklist was completed on 30. August 2022 using brg/, a tool made by the EQUATOR Network in collaboration with	nmons chnologie
59 60		For peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Ē

#### Comparison of anti-vascular endothelial growth factor treatment for myopia choroidal neovascularization: a systematic review and meta-analysis of randomized controlled trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-067921.R1
Article Type:	Original research
Date Submitted by the Author:	24-May-2023
Complete List of Authors:	Dong, Liming; Beijing Tongren Hospital, Department of Pharmacy Li, Guangyao; Beijing Tongren Hospital Song, Zhihui; Beijing Tongren Hospital Cheng, Xiao; Beijing Tongren Hospital Bai, Jie; Beijing Tongren Hospital Zhang, Chao; Beijing Tongren Hospital, department of pharmacy
<b>Primary Subject Heading</b> :	Ophthalmology
Secondary Subject Heading:	Ophthalmology
Keywords:	OPHTHALMOLOGY, CLINICAL PHARMACOLOGY, Medical retina < OPHTHALMOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Comparison of anti-vascular endothelial growth factor treatment for myopia choroidal neovascularization: a systematic review and meta-analysis of randomized controlled trials

Liming Dong<sup>1</sup>, Guangyao Li<sup>1</sup>, Zhihui Song<sup>1</sup>, Xiao Cheng<sup>1</sup>, Jie Bai<sup>1</sup>, Chao Zhang<sup>1</sup>

Running title: Anti-VEGF treatment for myopia CNV

Word count: 3521

Professor Chao Zhang; laural.zhang@yahoo.com

<sup>&</sup>lt;sup>1</sup> Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China **Correspondence to** 

#### ABSTRACT

**Objectives** To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularization (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.

**Data sources** PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022.

**Study selection** Randomized controlled trials (RCTs) comparing anti-VEGF with sham, photodynamic therapy (PDT) or PDT combination therapy in patients with myopia CNV were reviewed and selected. RCTs comparing visual acuity stabilization or disease activity as anti-VEGF retreatment criteria were also included in the study.

**Data extraction and synthesis** Two reviewers independently conducted data extraction and quality assessment. We used a random-effects model for all analyses. Primary outcomes included best-corrected visual acuity (BCVA) and central foveal thickness. Secondary outcomes included number of patients who gained more than 3 lines in BCVA, number of anti-VEGF injections and ocular adverse event (AE).

**Results** Seven RCTs involving 1007 patients were included. Compared to sham and PDT therapy, anti-VEGF therapy achieved better BCVA gains of -0.28 logMAR (95% CI -0.36 to -0.20, P < 0.00001) and -0.14 logMAR (95% CI -0.17 to -0.10, P < 0.00001), respectively. Both ranibizumab and bevacizumab improved patients' vision better than PDT therapy and no definitive increased risk of ocular AE was observed. Analysis of two small RCTs showed that PDT combination therapy had similar visual improvement and needed fewer anti-VEGF injections compared to anti-VEGF monotherapy (WMD=1.30; 95% CI 1.24 to 1.37, p<0.00001). Anti-VEGF retreatment guided by disease activity criteria resulted in comparable visual improvement and reduced anti-VEGF injections compared with retreatment guided by visual acuity stabilization (WMD=0.83; 95% CI 0.42 to 1.25, P < 0.0001).

**Conclusions** Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections.

PROSPERO registration number CRD42021292806.

**Key Words** anti-VEGF; myopia choroidal neovascularization; retreatment regimen; meta-analysis.

#### Strengths and limitations of this study

- This meta-analysis included all available data from the most recent RCTs and comprehensively compared anti-VEGF with different treatment strategies for myopic CNV.
- Our review included multicenter RCTs comparing the efficacy and number of injections of disease activity and visual acuity stabilization as anti-VEGF retreatment criteria to recommend superior anti-VEGF retreatment criteria.
- The number of included RCTs was relatively small, and some RCTs had small sample sizes, requiring larger relevant studies.
- The inconsistent follow-up time points may account for the heterogeneity of some parameters, which limits the generalizability of the study results.



#### **INTRODUCTION**

Pathologic myopia is characterized by excessive elongation of the eyeball, leading to various degenerative changes in the retina and visual deterioration <sup>1</sup>. Among the complications of pathologic myopia, choroidal neovascularization (CNV) and mechanical rupture of Bruch membrane are the most serious degenerative changes <sup>2</sup>. Pathologic myopia is the second cause of CNV after neovascular age-related macular degeneration (nAMD), with approximately 5.2% to 11.3% of pathological myopia patients developing to myopic CNV <sup>3</sup> <sup>4</sup>. Myopic CNV has a higher prevalence in Asian population, with most patients developing the disease at age 50 or younger, rather than in old age <sup>5</sup>. Without treatment, the majority of myopic CNV patients will develop a poor visual outcome. A 10-year follow-up study showed that over 95% of myopic CNV patients had reduced visual acuity (VA) to 0.1 or worse at 5 and 10 years after onset <sup>6</sup>.

Before the use of anti-VEGF therapy in myopic CNV, treatment strategies mainly included laser photocoagulation, verteporfin photodynamic therapy (PDT), and submacular surgery <sup>7-10</sup>. However, the clinical application of these approaches is limited by complications such as myopic CNV recurrence, scarring, atrophy, and choroidal ischemia <sup>7 11 12</sup>. PDT has been the most widely used treatment for myopic CNV since the Verteporfin in Photodynamic Therapy (VIP) study showed that patients treated with PDT had better visual outcomes over 12 months compared to placebo <sup>8</sup>. However, the 2-year follow up of the VIP trial reported no statistically significant benefit from PDT treatment and a high recurrence rate of intraretinal fluid after treatment <sup>9</sup>. Another study showed that 83% of PDT treated patients developed choroidal atrophy after 5 years <sup>13</sup>. Since anti-vascular endothelial growth factor (anti-VEGF) therapy become available, PDT has fallen out of favor and only considered when anti-VEGF therapy is contraindicated.

VEGF, a proangiogenic cytokine that stimulates the development of CNV, is abnormally increased in the eyes of myopic CNV patients <sup>14</sup>. Anti-VEGF binds to VEGF receptor to inactivate endogenous VEGF and inhibit the migration and Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

proliferation of vascular endothelial cell, thereby inhibiting neovascularization <sup>15</sup>. The earliest report of intraocular injection of anti-VEGF drugs for myopic CNV was in 2006 and has been increasingly used in recent years <sup>16</sup> <sup>17</sup>. Although previous studies have shown that anti-VEGF therapy leads to better vision, comparative studies mainly consist of non-RCTs and a small number of RCTs, which limits the strength to support clinical application <sup>18</sup> <sup>19</sup>. Furthermore, despite clinical approval of anti-VEGF therapy for myopia CNV, the optimal retreatment criteria have not been unified <sup>20</sup>.

In recent years, new RCTs about anti-VEGF therapy for myopia CNV have been published and long-term data on efficacy and safety have been accumulated. Most importantly, two large RCTs have been completed to compare the therapeutic effects of different anti-VEGF retreatment criteria <sup>21</sup> <sup>22</sup>. Our aim was to update the latest clinical evidence and to explore preferred anti-VEGF retreatment criteria for myopic CNV.

#### **METHODS**

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline <sup>23</sup>.

#### Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

#### Data sources and search strategy

The databases of PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched from inception to 31 July 2022. The meta-analysis protocol was approved and registered in PROSPERO website with a registration number of CRD42021292806. A range of MESH words and free terms regarding CNV, anti-VEGF, ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea), conbercept (Lumitin), RCT were used in all possible combinations to search for relevant articles. The search strategy is provided in the online supplementary material

 1. No language restriction was applied. We also manually searched the reference lists of included studies to identify other potentially eligible articles.

#### **Eligibility criteria**

We included the following published studies if they met the criteria: (1) patients with active myopia CNV (with spherical equivalent  $\geq$  -6.0 dioptres and an axial length  $\geq$  25.0 mm); (2) studies were RCTs that directly compared intravitreal anti-VEGF drugs with sham or PDT or PDT combination therapy for the treatment of patients with myopia CNV; (3) RCTs comparing VA stabilization or disease activity as anti-VEGF retreatment criteria were included, with VA stabilization criteria was defined as no change in best-corrected visual acuity (BCVA) as compared with the two preceding monthly visits and disease activity criteria was defined as vision impairment attributable to intraretinal or subretinal fluid or active leakage secondary to myopia CNV; (4) studies reported one or more of interest outcomes. Exclusion criteria were employed as follows: (1) patients were previously treated with several drugs; (2) comparative studies between different anti-VEGF drugs, noncomparative studies, animal studies or case reports; (3) unfinished studies or unavailable data.

#### Data extraction and quality assessment

Titles and abstracts were scanned independently by two reviewers using the selection criteria described above. Disagreements were discussed and if necessary, resolved by a third reviewer. Data were extracted in a prespecified data extraction form. The following data were extracted from the included articles: general data (title, first author, study design, inclusion and exclusion criteria), basic characteristics (age, sex, sample size), intervention groups, follow-up time, primary outcomes (BCVA and central foveal thickness (CFT)) and secondary outcomes (number of patients who gained more than 3 lines in BCVA, number of anti-VEGF injections, and number of serious or nonserious ocular adverse events (AEs)). The quality of the RCTs was assessed using the Cochrane risk of bias tool <sup>24</sup>.

#### Data synthesis and statistical analysis

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

The meta-analysis was conducted using Review Manager 5.3 supplied by Cochrane Collaboration (Oxford, United Kingdom). The weighted mean difference (WMDs) with 95% confidence interval (CIs) were measured for continuous data, while the risk ratios (RRs) with 95% CIs were measured for dichotomous data. Visual outcomes were measured using the Early Treatment Retinopathy study (ETDRS) chart and the data were converted to logarithmic visual acuity (logMAR) for analyses <sup>25</sup> <sup>26</sup>. Heterogeneity between studies was assessed using the I<sup>2</sup> test.  $I^2 > 50\%$  was defined as the presence of substantial heterogeneity <sup>27</sup>. Due to the possibility of heterogeneity being present between studies, a more conservative version of the random-effects model was applied. A value of p<0.05 was chosen as the significance level for outcome measures.

#### **RESULTS**

#### Literature search

A total of 3376 relevant articles were initially identified. After removing 841 duplicates, we screened the remaining 2535 articles and excluded 2497 articles based on the titles and abstracts. The remaining 38 articles were retrieved for full-text review, and seven eligible RCTs <sup>21</sup> <sup>22</sup> <sup>28-32</sup> were included in the meta-analysis (figure 1). Among the seven RCTs included, one RCT compared anti-VEGF with sham treatment, four RCTs compared anti-VEGF with PDT, and two RCTs compared anti-VEGF monotherapy with PDT combination therapy. Besides, two RCTs compared different anti-VEGF retreatment criteria guided by VA stabilization criteria or disease activity criteria, respectively.

#### **Study characteristics**

The basic characteristics of seven RCTs included are shown in table 1. The study included a total of 1007 participants. The followed-up duration was 12 to 24 months. The mean age ranged from 44.6 to 62.4 years, with 52.5% to 76.5% of female. The anti-VEGF treatments used in the included studies were intravitreal bevacizumab (IVB 1.25mg), ranibizumab (IVR 0.5mg) and aflibercept (IVA 2.0mg). The PDT

#### **BMJ** Open

monotherapy received standard fluence PDT (50 J/cm<sup>2</sup>), and the PDT combination therapy received reduced fluence PDT (25 J/cm<sup>2</sup>) in combination with intravitreal anti-VEGF.

For different anti-VEGF retreatment criteria, patient retreatment guided by VA stabilization criteria received anti-VEGF on day 1 and month 1, followed by monthly injections when there was a loss of BCVA. Patient retreatment guided by disease activity criteria received anti-VEGF on day 1, followed by monthly injections when disease activity was observed.

20	Study/	Study	NCT Trial	Patients	Sample Size	Mean Age	Sex	Intervention	Follow-up
21 22	Year	Design	No.		(Patient)	(Year)	(M/F)	Groups	(Months)
23 r	MYRROR	RCT	01249664	Subfoveal or juxtafoveal	121	58.2±13.3	29/92	IVA (2.0 mg);	
24 25	2014 <sup>28</sup>			CNV secondary to high				Sham (no Drug)	luq
26				myopia					- Bu
27	Parodi	RCT	None	Juxtafoveal CNV secondary	37	49.45	13/24	IVB (1.25 mg);	24
28 29	201029			to pathologic myopia				SF PDT (50 J/cm <sup>2</sup> )	
29 30	Moreno	RCT	00967850	Subfoveal and/or	42	None	None	IVB (1.25 mg);	24
31	201330			juxtafoveal CNV secondary				SF PDT (50 J/cm <sup>2</sup> )	arec
32				to pathologic myopia					10
33 34 R	ADIANCE	RCT	01217944	Subfoveal or juxtafoveal or	276	55.56±13.96	68/209	IVR (0.5 mg): guided	12
35	2014 <sup>21</sup>			extrafoveal CNV secondary				by VA stabilization;	an
36				to pathologic myopia				IVR (0.5 mg): guided	u ua
37								by disease activity;	
38 39								SF PDT (50 J/cm <sup>2</sup> )	
	RILLIANCE	RCT	01922102	Subfoveal or juxtafoveal or	457	51.2±12.7	146/311	IVR (0.5 mg): guided	12 <b>g</b>
41	201922			extrafoveal CNV secondary				by VA stabilization;	AIT
42 43				to pathologic myopia				IVR (0.5 mg): guided	rain
44								by disease activity;	9m
45								SF PDT (50 $J/cm^2$ )	an
46 47	Saviano	RCT	None	Subfoveal or juxtafoveal	34	62.4	8/26	IVB (1.25 mg);	12
47 48	201331			CNV secondary to				IVB (1.25 mg) + RF	
49				pathologic myopia				PDT*	
50	Rinaldi	RCT	01968486	Subfoveal or juxtafoveal	40	44.6±4.48	19/21	IVR (0.5 mg);	12     Including for uses related to text and gata mining, and similar technologies       12     12       12     12       12     12       12     12       12     12
51 52	2016 <sup>32</sup>			CNV secondary to				IVR (0.5 mg) +	
53				pathologic myopia				RF PDT (25 $J/cm^2$ )	gies
54		RCT,	randomized of	controlled trial; NCT, nationa	al clinical trial	; CNV, choroi	dal neovas	cularization; PDT,	
55		1 . 1							

Table 1 Characteristics of the included seven studies

photodynamic therapy; anti-VEGF, anti-vascular endothelial growth factor; M/F, male/female; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVA, intravitreal aflibercept; VA, visual acuity; SF PDT, standard fluence photodynamic therapy; RF PDT, reduced fluence photodynamic therapy.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **Risk of bias assessment**

Risk of bias assessment for included RCTs is shown in the online supplementary material 2. Two RCTs <sup>21 22</sup> were considered to be at low risk of bias for all domains. Most unclear risk of bias was assigned in domains of selection bias or detection bias <sup>28</sup> <sup>29 31</sup>. Two RCTs <sup>30 31</sup> were considered to be at high risk of bias for performance bias and attrition bias, respectively.

#### Anti-VEGF therapy versus sham

MYRROR study <sup>28</sup> compared aflibercept with sham treatment, and results were presented at the end of 6-month because sham group could receive aflibercept when needed. The results showed that compared with the sham group, patients in anti-VEGF treatment achieved significant better BCVA (WMD=-0.28 logMA; 95% CI -0.36 to -0.20, p<0.00001; figure 2) and CFT reduction (WMD=-66.80  $\mu$ m; 95% CI -114.87 to -18.73, p=0.006; figure 3. The number of patients who gained more than 3 lines in BCVA was significantly higher in the anti-VEGF treatment than in the sham treatment group (RR= 4.02, 95% CI 1.33 to 12.15, p=0.01; supplemental figure). BCVA was significantly improved in patients treated with anti-VEGF compared with the sham group (-0.24 ± 0.20 logMA vs 0.04 ± 0.19 logMA), and a greater proportion of patients achieved more than 3 lines in BCVA (38.89% vs 9.68%). In addition, anti-VEGF-treated patients had a substantially larger mean decrease in CFT than sham patients (-80.7 ± 83.7  $\mu$ m vs -13.9 ± 127.4  $\mu$ m).

The incidence of serious (p=0.55; table 2) and non-serious ocular AEs (p=0.13; table 2) were similar in anti-VEGF and sham treatment groups. There were 3 serious ocular AEs (only 1 macular hole in study eye) in anti-VEGF group and no event occurred in sham treatment group. The most common non-serious ocular AEs in anti-VEGF treated patients were mild conjunctival hemorrhage, punctate keratitis, eye pain and dry eye, but did not lead to the interruption of treatment.

**Table 2** Meta-analysis results of the number of anti-VEGF injections, serious and non-serious ocular adverse events

	Comparison	No. of RCTs	<b>Risk ratio</b>	Р	I <sup>2</sup> (%)	P for
--	------------	-------------	-------------------	---	--------------------	-------

	(no. of Patients)	(95% CI)			heterogeneit
The number of anti-VEGF injection	IS	1			
Anti-VEGF monotherapy vs	2(74) 31 32	1.30 (1.24,1.37)	0.00001	32	0.23
PDT combination therapy	a (505) 21 22		0.0001		0.00
Anti-VEGF retreatment criteria:	2(587) <sup>21 22</sup>	0.83 (0.42,1.25)	0.0001	0	0.38
VA stabilization vs Disease					
activity					
The number of serious ocular adver	se events				
Anti-VEGF therapy vs Sham	1(121) 28	2.46 (0.13,46.36)	0.55	—	—
Anti-VEGF therapy vs PDT	4(525) 21 22 29 30	0.81(0.11,6.10)	0.84	0	0.62
Anti-VEGF retreatment criteria:	2(587) <sup>21 22</sup>	1.06 (0.15,7.45)	0.96	0	0.96
VA stabilization vs Disease					
activity					
The number of non-serious ocular a	dverse events	·			•
Anti-VEGF therapy vs Sham	1(121) 28	0.57 (0.28,1.18)	0.13	—	-
Anti-VEGF therapy vs PDT	4(525) 21 22 29 30	1.02(0.77,1.36)	0.88	0	0.90
Anti-VEGF monotherapy vs	2(74) 31 32	1.57 (0.77,3.22)	0.22	_	_
PDT combination therapy					
Anti-VEGF retreatment criteria:	2(587) <sup>21</sup> <sup>22</sup>	1.04 (0.83,1.31)	0.72	0	0.41
VA stabilization vs Disease					
activity					

RCT, randomized controlled trial; anti-VEGF, anti-vascular endothelial growth factor; PDT, photodynamic therapy; VA, visual acuity.

#### Anti-VEGF therapy versus PDT

Four RCTs <sup>21</sup> <sup>22</sup> <sup>29</sup> <sup>30</sup> compared anti-VEGF with PDT treatment, with two studies comparing ranibizumab <sup>21</sup> <sup>22</sup> and the other two comparing bevacizumab <sup>29</sup> <sup>30</sup> with PDT treatment. For the RADIANCE and BRILLIANCE study <sup>21</sup> <sup>22</sup>, results were presented at the end of 3-month because patients in PDT group could receive ranibizumab when needed. A significant increase of BCVA from baseline was observed in both groups. Compared to PDT, the mean improvement of BCVA (WMD=-0.14 logMAR; 95% CI -0.17 to -0.10, p<0.00001, I<sup>2</sup>=68%; figure 2) and reduction of CFT (WMD=-44.32  $\mu$ m; 95% CI -59.85 to -28.79, p<0.00001, I<sup>2</sup>=20%; figure 3) were superior in anti-VEGF group. And the number of patients who gained more than 3 lines in BCVA was higher in anti-VEGF group (RR=2.42; 95% CI 1.68 to 3.50, p<0.00001, I<sup>2</sup>=0%; supplemental figure), too. More clinically meaningful VA improvements were obtained with either ranibizumab or bevacizumab treatment. Compared to PDT,

 patients treated with ranibizumab had a better mean BCVA of -0.13 logMAR and a greater reduction in CFT of 47.89  $\mu$ m; bevacizumab-treated patients had a better mean BCVA of -0.29 logMAR and a greater reduction in CFT of 24.90  $\mu$ m (supplementary material 3, figure 1 and 2).

Anti-VEGF group recorded 2 serious ocular AEs (1 retinal detachment and 1 retinoschisis) and PDT group recorded 1 endophthalmitis (p=0.84; table 2). This endophthalmitis occurred in a patient in the PDT group who received PDT on the first day followed by an injection of anti-VEGF. Therefore, endophthalmitis was considered to be related to anti-VEGF injection. The non-serious ocular AEs showed no evidence of a difference between the two groups (p=0.88; table 2), conjunctival hemorrhage and punctate keratitis were most commonly reported.

#### **Anti-VEGF monotherapy versus PDT combination therapy**

Two small RCTs <sup>31 32</sup> compared anti-VEGF monotherapy with PDT combination therapy. There was no evidence of differences in mean BCVA (WMD=0.07 logMAR; 95% CI -0.00 to 0.14, p=0.06, I<sup>2</sup>=61%; figure 2) and CFT (WMD=6.40  $\mu$ m; 95% CI -20.10 to 32.90, p=0.64; figure 3) between the two groups. The number of patients who gained more than 3 lines in BCVA (RR=0.92; 95% CI 0.57 to 1.49, p=0.74; figure 3) was similar in both groups, too. Patients in both the anti-VEGF monotherapy group and the PDT combination therapy group obtained significant visual function and anatomic improvements. Nevertheless, the anti-VEGF injections in PDT combination therapy was statistically fewer than anti-VEGF monotherapy group (WMD=1.30; 95% CI 1.24 to 1.37, p<0.00001, I<sup>2</sup>=32%; table 2). No serious ocular AEs were documented, but some mild non-serious ocular AEs were observed in both groups, including ocular hyperemia, myodesopsia, conjunctival hemorrhage and eye pain (p=0.22; table 2).

# Anti-VEGF retreatment criteria: VA stabilization versus disease activity

Two RCTs <sup>21</sup> <sup>22</sup> compared the therapeutic effect of different anti-VEGF retreatment criteria. No evidence of a difference in mean BCVA (WMD=-0.00 logMAR; 95% CI

#### **BMJ** Open

-0.04 to 0.03, p=0.91, I<sup>2</sup>=0%; figure 2) and CFT change (WMD=2.31 µm; 95% CI -11.46 to 16.08, p=0.74, I<sup>2</sup>=0%; figure 3) between the two groups. Similar results were obtained for the number of patients who gained more than 3 lines in BCVA  $(RR=1.07; 95\% \text{ CI } 0.90 \text{ to } 1.27, p=0.47, I^2=0\%; \text{ supplemental figure})$ . Interestingly, the number of anti-VEGF injections guided by disease activity criteria was significantly fewer than in VA stabilization criteria group (WMD=0.83; 95% CI 0.42 to 1.25, p<0.0001,  $I^2=0\%$ ; table 2). The mean change in BCVA (-0.24 ± 0.23 logMA vs  $-0.24 \pm 0.22 \log MA$ ) and patients who gained more than 3 lines in BCVA (47.74%) vs 45.00%) from baseline was similar in both anti-VEGF retreatment groups. For anatomical changes, clinically relevant decrease in CFT ( $-74.72 \pm 76.74 \,\mu\text{m}$  vs -77.13 $\pm$  97.24 µm) from baseline was observed in both groups.

Safety profile showed no evidence of a difference in patients between the two anti-VEGF retreatment criteria. There were 2 serious ocular AEs, respective 1 retinal detachment in VA stabilization criteria and 1 retinoschisis in disease activity criteria group. The most commonly reported non-serious ocular AE was conjunctival hemorrhage (p=0.72; table 2). ies

#### DISCUSSION

In this meta-analysis, we evaluated the efficacy and safety of anti-VEGF treatment and compared two different anti-VEGF retreatment criteria. Evidences showed that anti-VEGF was superior to improving VA compared to sham or PDT treatment. PDT combination therapy showed similar visual improvement and needed fewer anti-VEGF injections compared to anti-VEGF monotherapy. For different retreatment criteria, anti-VEGF retreatment guided by disease activity criteria could achieve similar visual gain and need fewer anti-VEGF injections compare to VA stabilization criteria. Therefore, this review can provide the latest update on the systematic review of anti-VEGF treatment and provide evidence for optimizing retreatment criteria for myopia CNV.

Myopic CNV was a progressive disease and VA in the sham treatment group became worse than at baseline without treatment <sup>21</sup>. The short-term treatment effect of PDT was remarkable, but the long-term effect was poor and the recurrence rate was high <sup>9</sup> <sup>13</sup>. Analysis results indicated that anti-VEGF therapy had a better visual and anatomical improvement than sham or PDT treatment. The analysis showed that both ranibizumab or bevacizumab improved patients' visual acuity better compared to PDT treatment. Moreover, the post hoc analyses of RADIANCE study demonstrated BCVA gain of anti-VEGF therapy was sustained over additional 36 months <sup>33</sup>.

When comparing anti-VEGF monotherapy, PDT combination therapy showed similar visual improvement with fewer anti-VEGF injections. The reduction in the number of anti-VEGF injections may be beneficial for patients who are unwilling or unable to participate in monthly monitoring visits. Patients may also benefit from a reduced risk of complications related to surgery as well as the low-cost benefits of anti-VEGF. Thus, combined PDT with anti-VEGF therapy may be an alternative for the treatment of myopia CNV patients. However, larger comparative studies with longer follow-up are needed to adequately compare the efficacy and cost-effectiveness of anti-VEGF monotherapy with PDT combination therapy.

For safety estimation, there was no evidence of a difference in the incidence of serious and non-serious ocular AEs between anti-VEGF therapy and other treatments. The most common ocular AEs of anti-VEGF treatment were mild conjunctival hemorrhage and punctate keratitis, which were well tolerated in myopic CNV patients. Although some cases reported that new onset myopic macular retinoschisis (MRS) may be a complication of anti-VEGF intravitreal therapy, only 1 MRS event was reported in MYRROR study, and another study also found there was no association between the new onset of MRS and anti-VEGF therapy <sup>34-36</sup>.

Currently, the guidance and consensus statement recommended anti-VEGF therapy for myopic CNV, but do not point out the definite criteria for retreatment <sup>12 20</sup>. Most clinical research refer to retreatment criteria guided by disease activity criteria (intraretinal or subretinal fluid or active leakage) or VA stabilization criteria (BCVA change), or both <sup>37-40</sup>. The use of different retreatment criteria may affect retreatment <sup>13</sup>

rates and the number of anti-VEGF injections. Fewer anti-VEGF injections can lead to lower risk of AEs, preferable compliance, and lower cost. Simultaneous monthly measurement of VA stabilization and disease activity to guide anti-VEGF retreatment are more accurate, but it also imposes a considerable economic burden on health systems. Therefore, it is crucial to determine optimal retreatment criteria, especially for myopic CNV patients in developing countries <sup>41</sup>.

Two multicenter RCTs <sup>21</sup> <sup>22</sup> compared different anti-VEGF retreatment criteria for myopic CNV. The results found that disease activity criteria had similar visual efficacy and safety compared to VA stabilization criteria, but the disease activity criteria required significantly fewer anti-VEGF injections. Analyzing the reasons, the anatomical changes that typically precede the actual VA loss, thereby anti-VEGF retreatment guided by disease activity criteria could control disease progression earlier and more sensitive than VA stabilization criteria <sup>42</sup> <sup>43</sup>. VA stabilization retreatment criteria required more frequent injections of anti-VEGF, which means higher treatment costs and increases the possibility of AEs. Thus, anti-VEGF retreatment guided by disease activity criteria may be a more preferred option for the treatment of myopic CNV.

However, there were some limitations in this meta-analysis. The number of included studies was relatively small, and some RCTs had small sample size. There was substantial heterogeneity in some parameters, partly due to inconsistent follow-up times of included RCTs. Besides, the followed-up duration was limited to 12-24 months, which were too short to catch more significant differences in progression of anti-VEGF therapy. Therefore, large, high quality and long-term clinical evidence is needed to support our view in the future.

#### CONCLUSIONS

The meta-analysis suggests that anti-VEGF is effective and well tolerated for improving VA in patients with myopic CNV comparing with sham and PDT therapy. Compared with VA stabilization criteria, anti-VEGF retreatment guided by disease Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **BMJ** Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

activity criteria can produce similar therapeutic efficacy and reduce anti-VEGF injections, which may be a more recommended retreatment criterion for myopic CNV patients. Moreover, considering the limitations of the relatively small number and size of studies, it remains uncertain whether the combination of PDT with anti-VEGF therapy can be a good alternative to anti-VEGF monotherapy.

to beet terien only

**Contributors** LD: reviewed literature, data collection, prepared and revised the manuscript. GL: supervision, data collection and data analysis. ZS: data collection and revised the manuscript. XC: data collection and data analysis. JB: data analysis and critical appraisal. CZ: supervision, critical appraisal and revised the manuscript.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

**Ethics approval** This study was conducted using published data and did not involve human participants directly. Therefore, this work is exempt of ethical review.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

iez oriz

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### REFERENCES

- 1 Flitcroft DI, He M, Jonas JB, *et al.* IMI-defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. *Invest Ophthalmol Vis Sci* 2019; 60:M20-M30.
- 2 Ng DSC, Ho M, Iu LPL, *et al.* Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. *Expert Opin Drug Saf* 2022; 21:43-54.
- 3 Wong TY, Ohno-Matsui K, Leveziel N, *et al.* Myopic choroidal neovascularisation: current concepts and update on clinical management. *Br J Ophthalmol* 2015; 99:289-96.
- 4 Wong TY, Ferreira A, Hughes R, *et al.* Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. *Am J Ophthalmol* 2014; 157:9-25.e12.
- 5 Ng DSC, Fung NSK, Yip FLT, et al. Ranibizumab for myopic choroidal neovascularization. *Expert Opin Biol Ther* 2020; 20:1385-1393.
- 6 Yoshida T, Ohno-Matsui K, Yasuzumi K, *et al.* Myopic choroidal neovascularization: a 10-year follow-up. *Ophthalmology* 2003; 110:1297-305.
- 7 Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. *Cochrane Database Syst Rev* 2005; (4):CD004765.
- 8 Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. *Ophthalmology* 2001; 108:841-52.
- 9 Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology 2003; 110:667-73.
- 10 Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. *Arch Ophthalmol* 2000; 118:344–350.
- 11 Hayashi K, Ohno-Matsui K, Shimada N, *et al.* Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic

#### **BMJ** Open

myopia. Am J Ophthalmol 2011; 151:137-147.

- 12 Ohno-Matsui K, Ikuno Y, Lai TYY, *et al.* Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. *Prog Retin Eye Res* 2018; 63:92-106.
- 13 Giansanti F, Virgili G, Donati MC, *et al.* Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. *Retina* 2012; 32:1547-52.
- 14 Toto L, Di Antonio L, Costantino O, *et al.* Anti-VEGF Therapy in Myopic CNV. *Curr Drug Targets* 2021; 221054-1063.
- 15 Hu Q, Li H, Du Y, et al. Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2019; 98:e14905.
- 16 Laud K, Spaide RF, Freund KB, *et al.* Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. *Retina* 2006; 26:960-3.
- 17 Corazza P, Kabbani J, Soomro T, *et al.* Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. *Eur J Ophthalmol* 2021; 31:2481-2487.
- 18 Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. *Retina* 2013; 33:1375-92.
- 19 Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 2016; 12:CD011160.
- 20 Cheung CMG, Arnold JJ, Holz FG, *et al.* Myopic choroidal neovascularization: review, guidance, and consensus statement on management. *Ophthalmology* 2017; 124:1690-1711.
- 21 Wolf S, Balciuniene VJ, Laganovska G, *et al.* RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. *Ophthalmology* 2014; 121:682-92.e2.

- 22 Chen Y, Sharma T, Li X, *et al.* Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. *Retina* 2019; 39:1985-1994.
- 23 Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 29:372:n160.
- 24 Higgins JP, Altman DG, Gøtzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
- 25 Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. *Retina* 2010; 30:1046-50.
- 26 Holladay JT. Visual acuity measurements. *J Cataract Refract Surg* 2004; 30:287-90.
- 27 Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003; 327:557-60.
- 28 Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. *Ophthalmology* 2015; 122:1220-7.
- 29 Parodi MB, Iacono P, Papayannis A, *et al.* Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. *Arch Ophthalmol* 2010; 128:437-42.
- 30 Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, et al. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. *Ophthalmology* 2013; 120:1510-1.e1.
- 31 Saviano S, Piermarocchi R, Leon PE, *et al.* Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. *Int J Ophthalmol* 2014; 7:335-9.
- 32 Rinaldi M, Semeraro F, Chiosi F, *et al.* Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.

#### **BMJ** Open

- 33 Tan NW, Ohno-Matsui K, Koh HJ, *et al.* Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the RADIANCE study. *Retina* 2018; 38:2228-2238.
- 34 Tufan HA, Gencer B, Kara S. Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation. *Clin Exp Optom* 2014; 97:178-80.
- 35 Lee JH, Lee SC, Kim SH, *et al.* Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. *Retina* 2017; 37:1516-1522.
- 36 Zhou Y, Yang S, Yuan Y, *et al.* Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after conbercept therapy: a post-hoc analysis. *Eye (Lond)* 2020; 34:523-529.
- 37 Tufail A, Narendran N, Patel PJ, *et al.* Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. *Ophthalmology* 2013; 120: 1944-1945.
- 38 Iacono P, Battaglia Parodi M, *et al.* Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization. *Retina* 2017; 37:1931-1941.
- 39 Li S, Ding X, Sun L, *et al.* Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. *Clin Exp Ophthalmol* 2019; 47:250-258.
- 40 Ng DS, Kwok AK, Tong JM, *et al.* Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. *Retina* 2015; 35:2457-68.
- 41 Parikh R, Pirakitikulr N, Chhablani J, et al. A multinational comparison of anti-Vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific. *Ophthalmol Retina* 2019; 3(1):16-26.
- 42 Hoerster R, Muether PS, Hermann MM, *et al.* Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. *Br J Ophthalmol* 2011; 20

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

95:1424-6.

43 Karasu B, Celebi ARC. The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization. *Int Ophthalmol* 2022; 42:2729-2740.

#### **Figure legends**

Figure 1 Flow diagram of study selection process that was conducted in PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov.

Figure 2 Forest plot of studies examining the mean change in BCVA (logMAR).

Figure 3 Forest plot of studies examining the mean change in CFT.




Figure 1 Flow diagram of study selection process that was conducted in PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov.

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.




Figure 2 Forest plot of studies examining the mean change in BCVA (logMAR).

169x110mm (300 x 300 DPI)

For peer re

		[experime			Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
2.1.1 Anti-VEGF thera									
MYRROR 2014	-80.7	83.7	90	-13.9	127.4			-66.80 [-114.87, -18.73]	
Subtotal (95% CI)			90			31	100.0%	-66.80 [-114.87, -18.73]	
Heterogeneity: Not a	pplicable								
Test for overall effect	: Z = 2.72 (P	= 0.006)							
2.1.2 Anti-VEGF thera	apy vs PDT								
BRILLIANCE 2019	-71.2	81.28	184	-29.1	75.57	91	63.6%	-42.10 [-61.57, -22.63]	
Moreno 2013	-50.4	65.72	22	-25.5	64.42	20	15.5%	-24.90 [-64.29, 14.49]	
RADANCE 2014	-77.6	110.67	116	-12	103.85	55	20.8%	-65.60 [-99.64, -31.56]	
Subtotal (95% CI)			322			166	100.0%	-44.32 [-59.85, -28.79]	◆
Heterogeneity: Chi <sup>2</sup> =	= 2.48, df = 2	(P = 0.29)	; I <sup>2</sup> = 209	%					
Test for overall effect	: Z = 5.59 (P	< 0.00001	)						
2.1.3 Anti-VEGF mon	otheranyvs	PDT com	hination	theram	,				
Rinaldi 2016	-85	41.7		-91.4	43.8	20	100.0%	6.40 [-20.10, 32.90]	
Subtotal (95% CI)	-05	41.7	20	-51.4	43.0	20		6.40 [-20.10, 32.90]	
Heterogeneity: Not a	nnlicable		20			20	1001070	0.40[-20.10, 02.00]	
Test for overall effect		= 0.64							
restion overall ellect	. 2 - 0.47 (i	- 0.04)							
2.1.4 Anti-VEGF retre									$\perp$
BRILLIANCE 2019	-79.4	71.39			85.93		72.4%	1.40 [-14.78, 17.58]	
RADANCE 2014	-66.6	84.98	105	-71.3	113.04	116	27.6%	4.70 [-21.52, 30.92]	
Subtotal (95% CI)			287			300	100.0%	2.31 [-11.46, 16.08]	<b>•</b>
Heterogeneity: Chi <sup>2</sup> =			; I <sup>2</sup> = 0%						
Test for overall effect	: Z = 0.33 (P	= 0.74)							
									-100 -50 0 50 100

Figure 3 Forest plot of studies examining the mean change in CFT.

169x93mm (300 x 300 DPI)

Search strategy
1. PubMed search strategy
Date: From inception to 31 July 2022
Search strategy:
#1 AntiVEGF [All Fields]
#2 Anti-VEGF [All Fields]
#3 "Vascular Endothelial Growth Factors"[Mesh Terms]
#4 "Vascular Endothelial Growth Factors"[All Fields]
#5 VEGFs [All Fields]
#6 ranibizumab [MeSH Terms]
#7 ranibizumab [All Fields]
#8 rhumab [All Fields]
#9 bevacizumab [MeSH Terms]
#10 bevacizumab [All Fields]
#11 Avastin [All Fields]
#12 altuzan [All Fields]
#13 vasi [All Fields]
#14 aflibercept [All Fields]
#15 aflibercept[Supplementary Concept]
#16 eylea [All Fields]
#17 "VEGF Trap" [All Fields]
#18 Zaltrap [All Fields]

1	
2 3	
4	#19 "AVE 0005" [All Fields]
5	
6 7	#20 conbercept [All Fields]
8	
9 10	#21 KH902 [All Fields]
11	
12	#22 "KH902 fusion protein"[Supplementary Concept]
13 14	
15	#23 Brolucizumab [Supplementary Concept]
16	
17 18	#24 Brolucizumab [All Fields]
19	#25 Decry [All Fields]
20	#25 Beovu [All Fields]
21 22	#26 RTH258 [All Fields]
23	#20 KT11258 [All Fields]
24 25	#27 ESBA1008 [All Fields]
26	
27	#28 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
28 29	
30	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
31	
32 33	OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
34	
35 36	#29 "Choroidal Neovascularization" [MeSH Terms]
37	
38	#30 "CNV" [All Fields]
39 40	
41	#31 mCNV [All Fields]
42	#31 mCNV [All Fields] #32 Choroid AND Neovascularization * [All Fields]
43 44	#32 Choroid AND Neovascularization * [All Fields]
45	#33 Choroidal AND Neovascularization *[All Fields]
46 47	
48	#34 #29 OR #30 OR #31 OR #32 OR #33
49	
50 51	#35 Controlled Clinical Trial [Publication Type]
52	
53	#36 Randomized Controlled Trial [Publication Type]
54 55	
56	#37 "Controlled Clinical Trial" [All Fields]
57 58	
59	#38 "Randomized Controlled Trial" [All Fields]
60	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#39 "Randomized Controlled Trial" [All Fields]

#40 RCT [All Fields]

#41 random\*[All Fields]

#42 trial [All Fields]

#43 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42

#44 #28 AND #34 AND #43 to beet tellow only

Items: 920

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	
3 4 5 6	2. EMBASE search strategy
7 8	Date: From inception to 31 July 2022
9 10 11	Search strategy:
12 13	#1 AntiVEGF [All Fields]
14 15 16	#2 Anti-VEGF [All Fields]
17 18	#3 'vasculotropin inhibitor'/exp
19 20 21	#4 vasculotropin [All Fields]
22 23 24	#5 'Vascular Endothelial Growth Factors' [All Fields]
24 25 26	#6 VEGFs [All Fields]
27 28 29	#7 'ranibizumab'/exp
30 31	#8 ranibizumab [All Fields]
32 33 34	#9 lucenti [All Fields]
35 36	#10 rhumab [All Fields]
37 38 39	#11 'bevacizumab'/exp
40 41	#12 bevacizumab [All Fields]
42 43 44	#13 Avastin [All Fields]
45 46 47	#14 altuzan [All Fields]
48 49	#15 vasi [All Fields]
50 51 52	#16 aflibercept [All Fields]
53 54	#17 'aflibercept'/exp
55 56 57	#18 eylea [All Fields]
58 59	#19 'VEGF Trap' [All Fields]
60	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#20 Zaltrap [All Fields]

#21 'AVE 0005' [All Fields]

#22 'conbercept'/exp

#23 KH902 [All Fields]

#24 'Brolucizumab'/exp

#25 Brolucizumab [All Fields]

#26 Beovu [All Fields]

#27 RTH258 [All Fields]

#28 ESBA1008 [All Fields]

#29 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR

#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21

OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28

#30 'Choroidal Neovascularization'/exp

#31 CNV [All Fields]

#32 mCNV [All Fields]

#33 (Choroid AND Neovascularization\*) [All Fields]

#34 (Choroidal AND Neovascularization\*) [All Fields]

#35 #30 OR #31 OR #32 OR #33 OR #34

#36 'controlled clinical trial'/exp

#37 'randomized controlled trial'/exp

#38 "Controlled Clinical Trial" [All Fields]

#39 "Randomized Controlled Trial" [All Fields]

1	
2	
3	
4 5	#40 RCT [All Fields]
6	
7	#41 random* [All Fields]
8	
9	#42 trial [All Fields]
10 11	
12	#43 #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42
13	
14	#44 #29 AND #35 AND #43
15	
16 17	
18	
19	L 1754
20	Items: 1754
21	
22 23	
23	
25	
26	
27	
28 29	
30	
31	
32	
33	Items: 1754
34 35	
36	
37	
38	
39 40	
40	
42	
43	
44	
45 46	
46 47	
48	
49	
50	
51 52	
53	
54	
55	
56	
57 58	
59	
60	

#### 3. The Cochrane Library search strategy

Date: From inception to 31 July 2022

Search strategy:

Search term: [Title Abstract Keyword]

#1 AntiVEGF

#2 Anti-VEGF

owth Factors #3 "Vascular Endothelial Growth Factors"

#4 VEGFs

#5 ranibizumab

#6 lucenti

#7 rhumab

#8 bevacizumab

#9 Avastin

#10 altuzan

#11 vasi

#12 aflibercept

#13 eylea

#14 "VEGF Trap"

#15 Zaltrap

#16 "AVE 0005"

#17 conbercept

#18 KH902

1	
2	
3	#10 D
4	#19 Beovu
5 6	
7	#20 Brolucizumab
8	
9	
10	#21 RTH258
11	
12	#22 ESBA1008
13	
14	"
15	#23 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
16	
17	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
18	
19	
20	OR #22
21	
22	#24 "Choroidal Neovascularization"
23	
24	
25	#25 CNV
26	
27	#26 mCNV
28	#20 IIICIVV
29	
30	#27 (Choroid AND Neovascularization*)
31	
32	#28 (Charaidal AND Nagyagaularization*)
33	#28 (Choroidal AND Neovascularization*)
34	
35	#29 #24 OR #25 OR #26 OR #27 OR #28
36	
37	#20 "Controlled Olinical Trial"
38	#30 "Controlled Clinical Trial"
39	
40	#31 "Randomized Controlled Trial"
41	
42	#22 D.C.T.
43 44	#32 RCT
45	
46	#33 random*
47	
48	#2.4 Ari 1
49	#34 trial
50	
51	#35 #30 OR #31 OR #32 OR #33 OR #34
52	
53	#26 #22 AND #20 AND #25
54	#36 #23 AND #29 AND #35
55	
56	
57	
58	T- (74
59	Items: 654
60	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 

#### 4. Clinicaltrial.gov search strategy

Date: From inception to 31 July 2022

Condition or disease: Choroidal Neovascularization

Other terms: AntiVEGF OR Anti-VEGF OR "Vascular Endothelial Growth Factors"

OR VEGFs OR ranibizumab OR lucenti OR rhumab OR bevacizumab OR Avastin OR altuzan OR vasi OR aflibercept OR eylea OR "VEGF Trap" OR Zaltrap OR "AVE 0005" OR conbercept OR KH902 OR Brolucizumab OR Beovu OR RTH258 OR

reliez oniz

**ESBA1008** 

Study type: Interventional Studies (Clinical Trials)

Study Results: Studies With Results

Status: Recruitment: Completed

Items: 44

Risk of bias assessment for included studies using Cochrane Collaboration's Tool.

#### 1. Risk of bias assessment for MYRROR (2014)<sup>1</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Unclear risk	Quote: "MYRROR was an
generation (selection bias)		international, phase III,
		multicenter, randomized,
~	5	double-masked, sham-controlled
		study.
		Eligible patients were randomized
	0	in a 3:1 ratio to receive intravitreal
		aflibercept or sham control
		(stratified by country). "
		The trial was described as
		randomised, but the method of
		sequence generation was not
		specified, we assessed as "
		Unclear risk " .
Allocation concealment	Unclear risk	Not reported
(selection bias)		
Blinding of participants	Low risk	Quote: "MYRROR was an

and personnel		international, phase III,
(performance bias) All		multicenter, randomized,
outcomes		double-masked, sham-controlled
		study."
Blinding of outcome	Low risk	Quote: "MYRROR was an
assessment (detection		international, phase III,
bias)	5	multicenter, randomized,
All outcomes	9	double-masked, sham-controlled
		study."
Incomplete outcome data	Low risk	Quote: "In total, 122 patients were
(attrition bias) All	2	randomized, of whom 91 received
outcomes	C	intravitreal aflibercept 2.0 mg and
		31 received sham; 122 patients
		were included in the safety set. In
		the full analysis set, 121 patients
		were included (90 patients
		received intravitreal aflibercept 2.0
		mg and 31 received sham). "
		Quote: "According to participant
		flow data on ClinicalTrials.gov, 5
		participants were withdrawn from

		the study and 1 participant did not
		complete visits to week 48 due to
		adverse events, both in the
		aflibercept group. However, only 1
		participant failed to fulfil
		requirements of full analysis set
O,		after randomisation. "
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)	0	reported.
Other bias	Low risk	No other bias identified.

1. Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology 2015; 122:1220-7.

### 2. Risk of bias assessment for Parodi et al (2010)<sup>2</sup>

Bias	Authors'	Support for judgement
	judgement	
Random sequence	Low risk	Quote: " Each patient was randomly
generation (selection bias)		allocated to 1 of the 3 treatment
		groups through a
		computer-generated number. "
Allocation concealment	Unclear risk	Not reported

(selection bias)		
Blinding of participants	Unclear risk	Not reported
and personnel		
(performance bias) All		
outcomes		
Blinding of outcome	Low risk	Quote: "At each scheduled
assessment (detection		examination, a complete
bias)	5	ophthalmological assessment was
All outcomes	0	carried out by an investigator who
	C.	had had no previous contact with
	6	the subject and was unaware of the
	Z	treatment previously
		administered. "
Incomplete outcome data	Low risk	Quote: "Fifty-four patients affected
(attrition bias) All		by juxtafoveal CNV in pathologic
outcomes		myopia were recruited; 4 patient
		were excluded because they could
		not attend the scheduled
		examinations; 3 patients were no
		recruited because they were affected
		by media opacity. "
Selective reporting	Low risk	All prespecified outcomes were

(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

2. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128:437-42.

#### 3. Risk of bias assessment for Moreno et al (2013)<sup>3,4</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "The randomisation was
generation (selection bias)		done by the promotor and was
	(P)	provided by the IOBA."
	4	Quote: "We performed a
		multicenter prospective study on
		55 highly myopic eyes from 55
		patients with CNV who were
		randomized to PDT (Group 1) or
		intravitreal bevacizumab (IVB)
		(Group 2)."
Allocation concealment	Low risk	Quote: "The randomisation was
(selection bias)		done by the promotor and was
		provided by the IOBA."

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1
2
3
4 5
5 6 7 8 9
6
7
8
9
10
11
12
10 11 12 13 14
17
14 15
15
16
13 14 15 16 17
18
19
20
21
22
23
20 21 22 23 24 25 26 27 28 29 30 31
25
26
27
28
29
30
31
32
32
33
34 35
35
36
3/
38
39
40
41
42
43
44
45
46
47
48
40 49
49 50
51
52
53
54
55
56
57
58
59
60

60

1

Blinding of participants	Low risk	Quote: "The study was doubled
and personnel		masked: (the follow-up physician
(performance bias) All		and the optometrist) and the
outcomes		patient were masked."
Blinding of outcome	Low risk	Quote: "The study was doubled
assessment (detection		masked: (the follow-up physician
bias)		and the optometrist) and the
All outcomes	5	patient were masked."
Incomplete outcome data	High risk	Quote: "Twenty-four eyes in group
(attrition bias) All	C	1 (86%) and 25 eyes in group 2
outcomes	10	(92.6%) completed 1 year of
	Ľ,	follow-up and 20 eyes in group 1
	(	(71.4%) and 22 eyes in group 2
		(78.6%) completed 2 years of
		follow-up."
		The loss to follow-up was $> 20\%$
		at 2 years and no reason was
		reported.
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

3. Ruiz-Moreno JM, López-Gálvez MI, Montero Moreno JA, et al. Intravitreal bevacizumab in

myopic neovascular membranes: 24-month results. Ophthalmology 2013; 120:1510-1.e1.

4. Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 2016; 12:CD011160.

#### 4. Risk of bias assessment for RADIANCE (2014)<sup>5</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "A randomization list was
generation (selection bias)		produced by Novartis Drug Supply
		Management using a validated
	0	system that automates the random
	1	assignment of treatment groups to
		randomization numbers in the
		specified ratio."
Allocation concealment	Low risk	Quote: "At enrollment, patients
(selection bias)		received the lowest available
		randomization number that then
		assigned them in a 2:2:1 ratio to 1
		of the 3 treatment groups."
Blinding of participants	Low risk	Quote: "Due to the different
and personnel		appearances and routes of

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

(performance bias) All	administra	tion between the
outcomes	treatments	, all patients received
	either shar	n injection or PDT shan
	in conjun	ction with the study
	treatment.	The PDT shan
	consisted	of intravenous injection
	of 5% dex	strose solution followed
	by light ap	plication of PDT. "
	Quote: "T	he treating investigato
	was unma	sked and administered
	the random	nized study medication
	per the p	rotocol; however, they
	were not	involved in any othe
	aspects of	the study and could no
	communic	ate details of the
	treatment."	
Blinding of outcome	Low risk Quote: "7	o ensure masking, 2
assessment (detection	investigato	rs were involved a
bias)	each stud	ly center. All study
All outcomes	assessmen	ts were made by the
	evaluating	investigator, VA
	assessor,	

		who were masked to the treatment
		assignment. "
Incomplete outcome data	Low risk	Quote: "6(5.7%) patients
(attrition bias) All		discontinued from the study
outcomes		1(0.9%) unsatisfactory therapeution
		effect; 1(0.9%) subject withdrew
		consent; 3(2.8%) lost to follow-up
	5	1(0.9%) protocol deviation.
	0	4(3.4%) patients discontinued
	C.	from the study: 2(1.7%) subjec
	6	withdrew consent; 1(0.9%) lost to
	Ľ,	follow-up; 1(0.9%) protoco
	(	deviation. "
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

5. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121:682-92.e2.

#### 5. Risk of bias assessment for BRILLIANCE (2019)<sup>6</sup>

Bias	Authors' judgement	Support for judgement
Random seque	ence Low risk	Quote: "Eligible patients were
generation (selection b	ias)	randomized 2:2:1 to one of three
		treatment arms using an interactive
		response technology system (see
		Figure, Supplemental Digital
		Content 3,
	6	http://links.lww.com/IAE/A901,
	0	which shows treatment schedule
	2	and study design)."
Allocation concealmer	nt Low risk	Quote: "Eligible patients were
(selection bias)	12	randomized 2:2:1 to one of three
	(	treatment arms using an interactive
		response technology system (see
		Figure, Supplemental Digital
		Content 3
		http://links.lww.com/IAE/A901,
		which shows treatment schedule
		and study design). "
Blinding of particip	ants Low risk	Quote: "BRILLIANCE was a
and perso	nnel	12-month, Phase III, randomized
(performance bias)	All	double-masked, multicenter

outcomes		active-controlled clinical trial."
		Quote: "For masking purpose
		sham ranibizumab or sham vPDT
		was applied."
		Quote: "All patients were masked
		to the study treatment."
Blinding of outcome	Low risk	Quote: "In addition, to fulfill the
assessment (detection	5	masking, there were at least two
bias)	0	investigators involved into the
All outcomes		study: masked (assessing)
	6	investigator performing al
	Z	assessments and capturing data
	(	and an unmasked (treating)
		investigator administering the
		randomized study treatment when
		needed according to the protocol."
Incomplete outcome data	Low risk	Quote: "9(4.9%) patients
(attrition bias) All		discontinued from the study in
outcomes		group 1: 1(0.5%) adverse event
		7(3.8%) subject withdrew consent
		1(0.5%) lost to follow-up."
		Quote: "9(4.9%) patients

		discontinued from the study in
		group 2: 2(1.1%) adverse event;
		3(1.6%) subject withdrew consent;
		2(1.1%) administrative problems;
		2(1.1%) physician's decision."
		Quote: "8(8.8%) patients
0		discontinued from the study in
	5	group 3: 7(7.7%) subject withdrew
	0	consent; 1(1.1%) physician's
	2	decision."
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)	Ľ,	reported.
Other bias	Low risk	No other bias identified.

6. Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. Retina 2019; 39:1985-1994.

#### 6. Risk of bias assessment for Saviano et al (2013)<sup>7</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Unclear risk	Quote: "Thirty-four patients were
generation (selection bias)		included in the study and then
		randomized into two different

		treatment groups."
		The trial was described as
		randomised, but the method of
		sequence generation was not
		specified, we assessed as "
		Unclear risk ".
Allocation concealment	Unclear risk	Not reported
(selection bias)	5	
Blinding of participants	Unclear risk	Not reported
and personnel	<u>9</u>	
(performance bias) All	6	
outcomes	Ľ,	Þ
Blinding of outcome	Unclear risk	Not reported
assessment (detection		2
bias)		0
All outcomes		
Incomplete outcome data	Low risk	No loss to follow-up.
(attrition bias) All		
outcomes		
Selective reporting	Low risk	All prespecified outcomes were
(reporting bias)		reported.
Other bias	Low risk	No other bias identified.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

7. Saviano S, Piermarocchi R, Leon PE, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study. Int J Ophthalmol 2014; 7:335-9.

#### 7. Risk of bias assessment for Rinaldi et al (2016)<sup>8</sup>

Bias	Authors' judgement	Support for judgement
Random sequence	Low risk	Quote: "Randomization was
generation (selection bias)	5	performed using
	0	computer-generated random
		numbers: each number
	Ċ,	corresponded to a type of
	· L	treatment."
Allocation concealment	Low risk	Quote: "Randomization was
(selection bias)		performed using
		computer-generated random
		numbers:each number
		corresponded to a type of
		treatment."
Blinding of participants	High risk	Quote: "The study was a
and personnel		prospective, comparative,
(performance bias) All		interventional, randomized,
outcomes		openlabel clinical trial."


Blinding of outcome	High risk	Quote: "The study was a		
assessment (detection		prospective, comparative,		
bias)		interventional, randomized,		
All outcomes		openlabel clinical trial."		
Incomplete outcome data	Low risk	Quote: "All patients completed the		
(attrition bias) All		follow-up at 48 weeks."		
outcomes				
Selective reporting	Low risk	All prespecified outcomes were		
(reporting bias)	C	reported.		
Other bias	Low risk	No other bias identified.		

8. Rinaldi M, Semeraro F, Chiosi F, et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2017; 255:529-539.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2

# 2. Ris



#### 2. Risk of bias summary for included RCTs.

### Meta-analysis results of different anti-VEGF versus PDT treatment for myopia CNV.

	Expe	erimen	tal	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
1.1.1 Ranibizumab th	hrapy vs	PDT							
BRILLIANCE 2019	-0.2	0.17	184	-0.09	0.16	91	66.0%	-0.11 [-0.15, -0.07]	
RADANCE 2014	-0.21	0.15	116	-0.05	0.19	55	34.0%	-0.16 [-0.22, -0.10]	
Subtotal (95% CI)			300			146	100.0%	-0.13 [-0.16, -0.09]	◆
Heterogeneity: Chi <sup>2</sup> =	= 1.94, df	= 1 (P	= 0.16)	; I <sup>2</sup> = 48	%				
Test for overall effect	: Z = 7.47	7 (P < 0	0.00001	)					
1.1.2 Bevacizumab t	hrapy vs	PDT							
Moreno 2013	-0.13	0.36	22	0.05	0.32	20	44.1%	-0.18 [-0.39, 0.03]	
Parodi 2010	-0.18	0.33	19	0.2	0.23	18	55.9%	-0.38 [-0.56, -0.20]	
Subtotal (95% CI)			41			38	<b>100.0</b> %	-0.29 [-0.43, -0.16]	
Heterogeneity: Chi <sup>2</sup> =	= 2.03, df	= 1 (P	= 0.15)	; I <sup>2</sup> = 51	%				
Test for overall effect	: Z = 4.19	9 (P < 0	0.0001)						
									-0.5 -0.25 0 0.25 0.5
									Favours [experimental] Favours [control]

Figure 1 Forest plot of studies examining the mean change in BCVA (logMAR).

	Favours	[experime	ental]		Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
2.1.1 Ranibizumab th	rapy vs PD	т							_
BRILLIANCE 2019	-71.2	81.28	184	-29.1	75.57	91	75.4%	-42.10 [-61.57, -22.63]	
RADANCE 2014	-77.6	110.67	116	-12	103.85	55	24.6%	-65.60 [-99.64, -31.56]	
Subtotal (95% CI)			300			146	100.0%	-47.89 [-64.79, -30.99]	◆
Heterogeneity: Chi <sup>2</sup> =	1.38, df = 1	(P = 0.24)	; <b>I</b> ² = 289	%					
Test for overall effect:	Z = 5.55 (P	< 0.00001	)						
2.1.2 Bevacizumab tl	nrapy vs P[	от							_
Moreno 2013	-50.4	65.72	22	-25.5	64.42	20	100.0%	-24.90 [-64.29, 14.49]	
Subtotal (95% Cl)			22			20	100.0%	-24.90 [-64.29, 14.49]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z=1.24 (P	= 0.22)							
									-100 -50 0 50 100
									Favours [experimental] Favours [control]
									Favours (experimental) Favours (control)

Figure 2 Forest plot of studies examining the mean change in CFT.

	Experime	ental	Contr	ol		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI	
3.1.1 Ranibizumab t	hrapy vs PD	т							
BRILLIANCE 2019	59	184	15	91	64.9%	1.95 [1.17, 3.23]		-₩-	
RADANCE 2014	50	116	8	55	35.1%	2.96 [1.51, 5.81]			
Subtotal (95% CI)		300		146	100.0%	2.30 [1.54, 3.45]			
Total events	109		23						
Heterogeneity: Chi <sup>2</sup> :	= 0.96, df = 1	(P = 0	.33); <b>I<sup>2</sup> =</b> [	0%					
Test for overall effect	: Z = 4.04 (P	< 0.00	01)						
3.1.2 Bevacizumab	hrapy vs Pl	т							
Moreno 2013	10	22	4	20	80.3%	2.27 [0.85, 6.11]		+-₩	
Parodi 2010	7	19	1	18	19.7%	6.63 [0.90, 48.69]			_
Subtotal (95% CI)		41		38	<b>100.0</b> %	3.13 [1.29, 7.59]			
Total events	17		5						
Heterogeneity: Chi2:	= 0.95, df = 1	(P = 0	.33); <b>I<sup>2</sup> =</b> [	0%					
Test for overall effect	: Z = 2.53 (P	= 0.01	)						
							<u> </u>		
							0.01	0.1 i 10	10
							Fa۱	ours [experimental] Favours [control]	

Figure 3 Forest plot of studies examining the number of patients who gained more than 3 lines in BCVA.




Figure 4 Forest plot of studies examining the serious ocular adverse events.

of 1	Experim		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events		Events	Total	weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
5.1.1 Ranibizumab th	nrapy vs PE	DT					
BRILLIANCE 2019	55	184	27	91	57.1%	1.01 [0.68, 1.48]	
RADANCE 2014	44	116	20	55	42.9%	1.04 [0.69, 1.59]	_ <b>_</b>
Subtotal (95% CI)		300		146	<b>100.0</b> %	1.02 [0.77, 1.36]	<b>•</b>
Total events	99		47				
Heterogeneity: Chi <sup>2</sup> =	0.01, df = 1	1 (P = 0	.90); l <sup>2</sup> = (	0%			
Test for overall effect	Z = 0.15 (F	P = 0.88	)				
5.1.2 Bevacizumab t	hrapy vs Pi	DT					
Moreno 2013	0	22	0	20		Not estimable	
Parodi 2010	0	19	0	18		Not estimable	
Subtotal (95% CI)		41		38		Not estimable	
Total events	0		0				
Heterogeneity: Not a	oplicable						
Test for overall effect	-	able					
							0.1 0.2 0.5 1 2 5 10
							Favours (experimental) Favours (control)

Figure 5 Forest plot of studies examining the non-serious ocular adverse events.

Risk Ratio

4.02 [1.33, 12.15]

4.02 [1.33, 12.15]

1.95 [1.17, 3.23]

2.27 [0.85, 6.11]

6.63 [0.90, 48.69]

2.96 [1.51, 5.81]

2.42 [1.68, 3.50]

0.92 [0.57, 1.49]

0.92 [0.57, 1.49]

1.09 [0.86, 1.39]

1.03 [0.80, 1.33]

1.07 [0.90, 1.27]

169x126mm (300 x 300 DPI)

0.01

0.1

Favours [experimental] Favours [control]

10

100

Risk Ratio

M-H, Fixed, 95% Cl

Experimental

35

35

59 184

10

7

50

126

3.1.3 Anti-VEGF monotherapy vs PDT combination therapy

12

12

81

56

137

Heterogeneity: Chi<sup>2</sup> = 0.11, df = 1 (P = 0.74); l<sup>2</sup> = 0% Test for overall effect: Z = 0.72 (P = 0.47)

Heterogeneity: Chi<sup>2</sup> = 2.06, df = 3 (P = 0.56); I<sup>2</sup> = 0% Test for overall effect: Z = 4.72 (P < 0.00001)

90

90

22

19

116

341

20

20

3.1.4 Anti-VEGF retreatment criteria: VA stabilization vs Disease activity

182

105

287

Study or Subgroup

MYRROR 2014

Total events

Moreno 2013

Parodi 2010

Total events

Rinaldi 2016

Total events

Subtotal (95% CI)

BRILLIANCE 2019

RADANCE 2014

Subtotal (95% CI)

Total events

Heterogeneity: Not applicable Test for overall effect: Z = 0.33 (P = 0.74)

RADANCE 2014

Subtotal (95% CI)

Subtotal (95% CI)

3.1.1 Anti-VEGF therapy vs Sham

Heterogeneity: Not applicable Test for overall effect: Z = 2.46 (P = 0.01) 3.1.2 Anti-VEGF therapy vs PDT BRILLIANCE 2019

Control Events Total Events Total Weight M-H, Fixed, 95% Cl

3

3

15 91

4 20 11.6%

1 18

8 55 30.0%

28

13

13

75 184

60

135

184

20 100.0%

116

300 100.0%

31 100.0%

31 100.0%

55.5%

2.8%

100.0%

20 100.0%

56.7%

43.3%

1 2	
3	
4	
5 6	
7	
8	
9 10	
11	
12	
13 14	
15	
16 17	
18	
19	
20 21	
22 23	
23	
24 25	
26	
27 28	
29	
30	
31 32	
33	
34 35	
36	
37	
38 39	
40	
41 42	
43	
44	
45 46	
47	
48 49	
50	
51	
52 53	
54	
55 56	
56	

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## Reporting checklist for systematic review (with or without a meta-analysis).

Based on the PRISMA guidelines.

#### Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMAreporting guidelines, and cite them as:

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM,
Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW,
Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting
P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

33 34						
35 36 37 38			Reporting Item	Number		
	Title			, Al trair		
39 40 41	Title	<u>#1</u>	Identify the report as a systematic review	1ing, an		
42 43	Abstract			d sim		
44 45 46 47	Abstract	<u>#2</u>	Report an abstract addressing each item in the PRISMA 2020 for Abstracts checklist	Al training, and similar technologies. 2		
48 49	Introduction			logies		
50 51 52 53 54 55 56 57 58 59 60	Background/rationale	<u>#3</u>	Describe the rationale for the review in the context of existing knowledge	4,5		
	Objectives	<u>#4</u>	Provide an explicit statement of the objective(s) or question(s) the review addresses	5		
	Methods Fo	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			

#### BMJ Open

1 2 3	Eligibility criteria	<u>#5</u>	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses
4 5 7 8 9 10	Information sources	<u>#6</u>	Specify all databases, registers, websites, organisations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted
11 12 13 14 15	Search strategy	<u>#7</u>	Present the full search strategies for all databases, registers, and websites, including any filters and limits used
16 17 18 19 20 21 22 23 24 25	Selection process	<u>#8</u>	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and, if applicable, details of automation tools used in the process
$\begin{array}{c} 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\end{array}$	Data collection process	<u>#9</u>	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and, if applicable, details of automation tools used in the process
	Data items	<u>#10a</u>	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (for example, for all measures, time points, analyses), and, if not, the methods used to decide which results to collect
	Study risk of bias assessment	<u>#11</u>	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and, if applicable, details of automation tools used in the process
	Effect measures	<u>#12</u>	Specify for each outcome the effect measure(s) (such as risk ratio, mean difference) used in the synthesis or presentation of results
58 59 60	Synthesis methods	#13a or peer rev	Describe the processes used to decide which studies view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

5,6

BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 July 2023. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. 6 6 6

#### BMJ Open

1 2 3 4			were eligible for each synthesis (such as tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5))
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	Synthesis methods	<u>#13b</u>	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics or data conversions
	Synthesis methods	<u>#13c</u>	Describe any methods used to tabulate or visually display results of individual studies and syntheses
	Synthesis methods	<u>#13d</u>	Describe any methods used to synthesise results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used
	Synthesis methods	<u>#13e</u>	Describe any methods used to explore possible causes of heterogeneity among study results (such as subgroup analysis, meta-regression)
	Synthesis methods	<u>#13f</u>	Describe any sensitivity analyses conducted to assess robustness of the synthesised results
31 32 33 34 35 36	Reporting bias assessment	<u>#14</u>	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases)
37 38 39 40	Certainty assessment	<u>#15</u>	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome
40 41 42 43 44 45 46 47 48	Data items	<u>#10b</u>	List and define all other variables for which data were sought (such as participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information
49 50	Results		
51 52 53 54 55 56 57 58 59	Study selection	<u>#16a</u>	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram (http://www.prisma- statement.org/PRISMAStatement/FlowDiagram)
60	Fo	r peer rev	iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5	Study selection	<u>#16b</u>	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded	BMJ Open: first
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Study characteristics	<u>#17</u>	Cite each included study and present its characteristics	7 bilis
	Risk of bias in studies	<u>#18</u>	Present assessments of risk of bias for each included study	shed as 10. ∞ Prot
	Results of individual studies	#19	For all outcomes, present for each study (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (such as confidence/credible interval), ideally using structured tables or plots	BMJ Open: first published as 10.1136/bmjopen-2022-067921 on 20 7 7 8 Protected by copyright, including for 1 1 8-11 8-11 8-1
20 21 22 23 24 25	Results of syntheses	<u>#20a</u>	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies	July Ense uses
25 26 27 28 29 30 31 32 33 34 35 36 37	Results of syntheses	<u>#20b</u>	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (such as confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect	2023. Downloaded from eignement Superieur ( <i>A</i> related to text and data -1 8- 8- 8-
	Results of syntheses	<u>#20c</u>	Present results of all investigations of possible causes of heterogeneity among study results	8-11 mining, Al
38 39 40 41	Results of syntheses	<u>#20d</u>	Present results of all sensitivity analyses conducted to assess the robustness of the synthesised results	Al training, au
42 43 44 45 46	Risk of reporting biases in syntheses	<u>#21</u>	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed	njopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de Al training, and similar technologies. 11,12 11,12 13
47 48 49 50 51 52 53 54 55 56 57 58	Certainty of evidence	<u>#22</u>	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed	nologies. 8-11
	Discussion			gence
	Results in context	<u>#23a</u>	Provide a general interpretation of the results in the context of other evidence	11,12 Bibliograp
	Limitations of	<u>#23b</u>	Discuss any limitations of the evidence included in the	13 ue
59 60	Fo	r peer rev	iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	de I

**BMJ** Open

			BMJ Open	Page 58 of 57
1	included studies		review	BMJ
2 3 4 5 6 7 8 9 10	Limitations of the review methods	<u>#23c</u>	Discuss any limitations of the review processes used	BMJ Open: first published
	Implications	<u>#23d</u>	Discuss implications of the results for practice, policy, and future research	13 13
	Other information			as 10.1 Prote
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Registration and protocol	<u>#24a</u>	Provide registration information for the review, including register name and registration number, or state that the review was not registered	as 10.1136/bmjopen-2022-067921 on 20 July Ens Protected by copyright, including for uses ഗ്ര
	Registration and protocol	<u>#24b</u>	Indicate where the review protocol can be accessed, or state that a protocol was not prepared	022-06792 ght, includ
	Registration and protocol	<u>#24c</u>	Describe and explain any amendments to information provided at registration or in the protocol	1 on 20 July Ens n/a n/a
	Support	<u>#25</u>	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review	2023. Down eignement related to t
	Competing interests	<u>#26</u>	Declare any competing interests of review authors	nloaded fr Superieu text and d 14
	Availability of data, code, and other materials	<u>#27</u>	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review	from http://bmjopen.bmj.com/ on ur (ABES) . data mining, Al training, and simi 4 1
40 41 42	Notes:			j.com/ , and s
43 44	• 20d: supplement 2	2		on June imilar tec
45 46 47 48 49 50 51 52 53 54 55 56 57 58	Attribution License	e CC-BN	ISMA checklist is distributed under the terms of the Creative Con (. This checklist was completed on 30. August 2022 using org/, a tool made by the EQUATOR Network in collaboration with	nmons thnologie
59 60	F	or peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	e 